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INTRODUCTION 
The role of prolactin (PRL) is now well established in the induction and 
promotion of many experimental mammary tumours (Welsch and Nagasawa, 
1977). However, the role of PRL and other anterior pituitary hormones in 
the pathogenesis of human breast cancer is not fully elucidated. PRL has been 
suspected to play a major role in stimulating the growth of some human breast 
cancers (CHermite M and LHermite-Baleriaux M, 1988). Jick et al. (1974) 
reported increased incidence of breast tumours as a result of clinical use of 
dopamine antagonists such as Rauwolfia drugs and the Phenothazines which 
leads to elevation of PRL secretion but this finding was contradicted by other 
studies (Macketal, 1975, Wagner and Mantel, 1978; Seth, 1982). 
Breast may be the target organ for various peptide hormones secreted 
from the anterior pituitary. PRL is one of the principal hormones regulating 
the alveolar function of the mammary gland (Anderson R.R., 1974). Breast 
may also undergo changes in response to the secretion of gonadotrophic 
hormones (LH and FSH) as well. The changes in leutinizing hormone (LH), 
pulsing mechanism or the 'firing rate of pituitary hormones' are believed to 
be responsible for the onset of puberty (Wildt et al, 1980) but whether such 
changes at the hypothalamic-pituitaiy- ovarian axis, are responsible for breast 
stromal development is unknown. Since the breast cells were shown to 
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possess specific binding sites for estrogens and progesterone (McGuire et al., 
1977), the effect of LH and follicular stimulating hormones (FSH) on the 
breast tissue may be through their effect on the ovarian secretion. 
PRL is known to exert several physiologic actions on human breast cells 
(Shiu and Friesen, 1980) but apart from a few case reports (Brown et al., 
1982, Rowe PH, 1984) epidemiologic evidence of breast pathology in patients 
with hyperprolactinaemia is scant. 
Luteal insufficiency which may be caused by hypierprolactinaemia (Sep-
pala et al., 1976) has been reported to be associated with breast disease 
(Mauvais-Jarvis et al., 1979). A number of studies of plasma PRL level have 
been performed (Boyns et al, 1973, Kwa et al, 197A; Sheth et al, 1975; Watt 
Boolsen, 1981; Simian B, 1982; Walsh eta/., 1984b; Wang eta/., 1987) but 
the results of these studies present a mixed picture. This was obvious on 
account of a very subtle hormonal changes, if any, that exist in these patients. 
The pulsatile secretion of hormones, diurnal variation in secretion, measure-
ment errors, non standard protocols, etc. made it indeed very difficult to 
interpret these findings. 
The importance of PRL receptors as an index of responsiveness of the 
tumour tissue has been established in recent year^as hormone influence cells 
by first binding to high affinity receptor protein located either on the cell 
surface or in the cell interior. Evaluafion of the capacity of hormone receptors 
as an index of response of treatment with either hormone administration or 
endocrine ablation is clearly of clinical importance. There are several climcal 
reports of treating benign breast disease by PRL inhibitor and dopamine 
agonist drug, bromocriptine (Mansel et al., 1980). Also Leutinizing hormone 
releasing hormone (LH-RH) analogue has been shown to be effective in 
treatment of advanced breast cancer (Klign et al., 1985). 
PRL binding sites have been reported to be present in breast tumours 
(CHermite-Baleriaux and liHermite, 1984; Kumar eta^, 1987) but it is un-
known whether other peptide hormone LH and FSH have any direct action 
on the breast tissue. In view of the fact that paracrine like activity takes place 
in endocrine target organs it was hypothesised that specific binding of peptide 
hormone of anterior pituitary may be seen in the breast tissue and breast 
cancer cells. Therefore, in the present study, binding capacity of breast tissue 
for various peptide hormones in breast were ascertained immunocytochemi-
cally and biochemically. Such a knowledge, it is envisaged, will provide basis 
for further research in this area and help to evaluate newer therapeutic 
modalities. 
REVIEW OF LITERATURE 
2.1 HORMONAL CONTROL OF BREAST AT VARIOUS 
STAGES IN WOMEN'S LIFE 
The major endocrine changes in girls occur at the time of puberty which 
begins at the age of 10 to 12 years (Styne and Gnimback, 1978). The 
microarchitecture pattern of breast tissue changes in response to hormonal 
changes throughout the menstrual cycle and during the life of the women 
(Vogel et al, 1981). The changes in LH pulsing mechanism or the 'firing rate 
of pituitary hormones' are believed to be responsible for the onset of puberty 
(Boyar et al, 1972, Wildt et al, 1980) but whether such changes are respon-
sible for breast stromal development is unknown. 
As menarche occurs, initially, the great majority of cycles are 
anovulatory, resulting in estrogen excess period. These estrogens induce the 
growth and maturation of breast and genital organs. The physiological effects 
of estrogens on the maturing breast is to stimulate longitudinal ductal growth 
of ductal epithelium. Latei; progesterone produced by corpus luteum during 
the ovulatory cycles stimulates lobuloalveolar proliferation of the breast. 
During the menstrual cycles, periodic changes take place in mammary 
tissue under the influence of sex steroid hormone. The complex interplay of 
estrogen and progesterone, secreted during the follicular phase and the luteal 
phase under the influence of FSH and LH takes place on breast tissue to bring 
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about a differential growth of its various components. 
An extensive ductulo-lobular alveolar growth takes place during preg-
nancy under the influence of estrogen, progesterone, PRL and gonadotropin. 
The level of PRL in blood goes on increasing during pregnancy and becomes 
almost 3 to 5 times the normal value. 
The action of PRL on cell multiplication and the synthesis oi milk 
protein, lactose and milk fats is affected by a number of other hormones either 
directly or indirectly (Fig. 2.1). As lactation initiates, reduction in placental 
lactogen and sex steroids hormone occurs. The secretion of PRL inhibiting 
factor (PIF) from the hypothalamus into the hypothalamoadenohypophyseal 
portal system decreases as a result of which PRL secretion by pituitary 
lactotrophs further increases and with the help of growth hormone (GH), 
insulin, Cortisol, PRL converts mammary epithelial cells from a pre-secretory 
to a secretory state of lactation. The release of PRL is maintained by suckling. 
Following removal of the infant from the breast feeding, the gland returns to 
an inactive state and as milk is no longer synthesised and removed, PRL and 
oxytocin release is not stimulated, thereafter the secretory activity of the 
lactogenic epithelium decreases. 
After menopause, the decrease in ovarian secretion of estrogen and 
progesterone causes progressive involution of the ductular and glandular 
components of the breast. There is quantitative decrease in the number and 
size of the glandular elements of the breast, with the epithelium of the lobule 
and duct becoming hypoplastic or atrophic. Apocrine change and microcysts 
are also frequently seen at this stage. This results in an increased proportion 
of adipose tissue and connective tissue. 
Fig. 2.1: Mammary gland is a target organ for a number of 
hormones. PRL and in some species PL (Placental 
lactogen) controls mammary activity directly. PL also 
stimulates SM (Somatomedian production by liver). E2 
(Estrogen) and Pg (Progesterone) are responsible for 
the differentiation of the mammary gland. E2 also have 
a role in producing growth factors (GF) Pg also 
inhibits lactation. Adrenal glucocorticoids synergised 
all the actions of PRL. T^ and T^ (Thyroid hormone) are 
both inhibitory and stimulatory. OXY (Oxytocin) affects 
lactation. SM (Somatomedian) and INS (Insulin) are 
involved in cell multiplication. 
ADRENALS OVARIES LIVER PITUITARY PUCENTA THYROID PANCREAS 
Glucocorticoids Pg E2 GF SM GH PRL OCY PL Pg E2 T3 T4 INS 
MAMMARY 
GLAND 
Cell Multiplication Milk fat synthesis 
Protein Lactose 
Synthesis synthesis 
Fig. 2.1: Mammary Gland: A Target Organ for various Hormones 
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2.2 ROLE OF HORMONES IN MAMMARY TUMORIGENESIS 
The breast or mammary glands of mammals are important for the 
survival of the nev^ bom and thus of the species. As described previously, 
breast undergoes changes throughout the life of women and thus is affected 
by various hormones like estrogen, progesterone, androgen, GH, PRL, insulin, 
corticosteroids, glucosteroids and thyroxine. The reproductive endocrine 
system which changes during the menarche, menopause and child birth may 
contribute to the aetiology and pathogenesis of breast cancer (Mac Mohan 
etal, 1973). Further; diet (Aslyworth etal, 1984), obesity (Henderson 
et al, 1984) and radiation induction (Baverstock etal, 1981) are also 
associated with the risk of development of breast disease or breast cancer. The 
UK National case control study group reported an increased risk of breast 
cancer associated with oral contraceptive (UK National Case Control Study 
Group, 1990). 
Considerable evidence has now accumulated from animal models, 
epidemiological studies and direct hormone measurement studies in popula-
tion at risk which has led to the hypothesis that reproductive hormones 
contribute mainly to the aetiology and pathogenesis of breast cancer. It was 
reported by Korenman^(1980) that in an apporpriate hormonal environment 
the mammary carcinoma was induced by a single exposure of the carcinogenic 
agent, dimethyl benzanthracene (DMBA). This appropriate hormonal en-
vironment was thought to have been provided by estrogen unopposed by the 
presence of progesterone and sufficient amount of anterior pituitary hor-
mones, particularly PRL. 
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The first study which developed the concept that hormones can cause 
or increase the incidence of neoplasia was done by Bittner JJ (1948) on 
experimental animals while studying the relationship of estrogen and mam-
mary cancer. Later on, in humans, it was observed that single and nulliparous 
women are at increased risk of breast cancer (Logan WPD, 1953). Moreovei; 
women who had their ovaries removed before the age of 40 or 45 and thus 
had artificial menopause have a reduced risk of breast cancer (Tichopolous 
et al., 1972). Further reproductive disturbances in animals as a result of 
mastectomy indicates the influence of hormones in breast pathology 
(Diamond et al, 1982). Recent studies have shown that radical mastectomy 
is followed by hyperprolactinemia in most of the breast cancer patients (Wang 
et al, 1986; Bami et al, 1987). These results indicated that there may be a 
significant endocrine abnormality in women with breast cancer but studies 
have not convincingly demonstrated elevated production or serum levels of 
either estrogen (Shore et al, 1983) or PRL (Franks et al., 1974; Sheth et al, 
1975) in breast cancer patients. The changes thus appear subtle. 
Sherman & Koreman (1974) put forward a hypothesis attempting to 
provide a pathophysiological interpretation of the various endocrine related 
risk factors of breast cancer (Table 2.1). 
Table 2.1 
Increased 
Late first pregnancy 
Nulliparity 
Early menarche 
Late menopause 
Obesity 
Low androgen 
excretion | 
Decreased 
Early first pregnancy 
Castration 
Orient?] 
No effect 
Oral contraceptives 
Lactafion 
, ( 
10 
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The most widely held view for the genesis of this hypothesis is that there 
is an imbalance between estrogen and progesterone in certain stages of life 
of women. Koreman S.G. (1980) in the 'Oestrogen Window Hypothesis' 
suggested that exposure of the breast to unopposed estrogen during the post 
menarchial or pre menopausal years increases the risk of breast cancer. Higher 
risk during late first pregnancy, nulliparity, obesity, low androgen secretion 
may also be due to the same reasons. 
The unopposed estrogen may be due to short luteal phase or abnormal 
ovarian follicular maturation resulting in irregular or deficient progesterone 
production by corpus luteum, short luteal phase cycles (Sherman and 
Koreman, 1974a) that are common cause of endocrine infertility in young 
women, are often accompanied with an excess PRL secretion (Askel S., 1980). 
Long follicular phase cycle though producing full ovulation also demonstrate 
prolonged unopposed estrogen stimulation, post menarchial cycles and 
premenopausal cycles are irregular in length of luteal or follicular phase, thus 
during these periods women are exposed for longer time to excess estrogen 
production and deficient or no progesterone secretion. Early first pregnancy 
on the other hand, may be considered to be protective as normal hormonal 
environment is established during this period. 
Estrogen which stimulates ductal proliferation and increases PRL recep-
tors in mammary gland are not by themselves mutagenic but they promote 
breast cellular susceptibility to neoplastic transformation, progesterone on 
the other hand opposes estrogen action and thus is considered to have a 
protective role in developing breast cancer. 
-11 
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MENARCHE AND BREAST CANCER 
A significanrly higher risk of developing breast cancer has been found 
among women with an early age at menarche in case control study, the risk 
ratio being of the order of 1.5 (Stazzewski J., 1971), later other studies also 
supported this view (Mac Mohan et ai, 1973; and Grey et al, 1979) though 
the difference between the average age at menarche of breast cancer cases 
and that of controls was found to be of only few months yet this difference at 
early age may result in two fold increase of risk of breast cancer (Pike et al, 
1983) but it was observed that it was not only the age at onset of menstruation 
that determines the risk but also the age when 'regular* menstruation was first 
established is importanLas regular ovulatory cycles increases women's risk of 
breast cancer (Henderson et al, 1985). The risk of breast cancer was more 
than double in women who had their regular menses within one year of 
menarche than in women having menarche at the same year but had a delay 
of 5 years for their menses to become regularised i.e. women with early 
menarche and rapid establishment of regular cycle had four fold increased 
risk than women with late menarche and longer period of establishment of 
regular cycles (Henderson et al, 1981). The women with later menarche were 
more likely to have anovular cycles than women with early menarche, given 
the same number of elapsed years since menarche (MacMohan et al, 1982). 
Apter and Vihko in 1983 confirmed this finding while studying the relation 
between menarche, ovulatory cycle and breast cancer in 200 school going 
giris. Thus contraiy to the belief of Korenman^(1980), greater number of 
ovulatory cycles increases a women's risk of breast cancer as in these normal 
luteal phase there are greater levels of cumulative estrogen which in turn is 
12 
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risk determinant factor (Venturoli et al, 1986; Henderson et al, 1985). No 
relationship had been found between PRL level and age at menarche (Yu 
etal, 1981). 
MENOPAUSE AND BREAST CANCER 
Late menopause having irregular ovulatory cycles and excess estrogen 
is also a breast cancer risk (Treolar et al, 1967). The M o^men Vk^ hose normal 
menopause or artificial menopause occured before the age 45 years had only 
one half the breast cancer risk of those whose menopause occurred after the 
age of 55 (Trichopoulous etal, 1972). This was explained,as before 
menopause in women the menstrual cycle becomes irregular resulting in a 
period of unopposed estrogenic stimulation of upto 8 years. If the menopause 
is delayed the women is subjected to extended exposure to cumulative 
estrogen and thus to the risk of breast cancer (Sherman et al,1976). The 
characteristics that predict risk of this cancer diagnosed before and after the 
menopause are more or less the same except few like weight and height 
(Paffenbarer et a/., 1980). 
PREGNANCY AND BREAST CANCER 
There is a complex relationship between breast cancer risk and age at 
first birth. Some workers (Choi etal, 1978) have shown no association 
between them but others have strongly associated the two. There is a striking 
relationship between the age at first birth and breast cancer risk, late age at 
first birth being atbvddi&l with gif-iei Ldir.er risk (MacMohan et al, 1970). 
Women having their first full term pregnancy (FFTP) at the eariy age had 
about one third risk of breast cancer than the women delaying their first 
13 
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pregnancy until the age of 30 or later A reanalysis of the same data with 
multivariate method showed that, even though age at first birth was the most 
important factor, age at subsequent birth had additional, independent effect 
(Trichopoulous et al, 1983). 
Inverse relationship between breast cancer and parity had also been 
stated CTulinuis et al, 1978) but the incomplete pregnancies before the FFTP 
did not have any protective effect (MacMohan et al, 1970). Even the first 
trimester abortion or a miscarriage before the FFTP doubles the risk of breast 
cancer (Pike et al., 1981). The reverse of this i.e. abortions after FFTP did not 
carry any increased risk (Hadjimichael et al, 1986). 
The long term protective effect could arise through FFTP causing either 
structural changes in breast (Russo et al, 1982) or/and long term changes in 
the hormone level and their receptors. It is the duration of time between 
menarche and first complete pregnancy that is important and critical (Mac-
Mohan and Cole, 1972). The longer this period, the longer will be the time 
for which the stem cells (which later mutate to cancer cells) that are increased 
in number and then undergo a certain fluctuation in number with each ovarian 
cycle until the first pregnancy, will be exposed to promoters (Cairns J., 1975). 
Drife J. (1981,1986) had proposed that it occurs because of differential 
responsiveness of breast tissue before and after the FFTP to the protective 
effects of progesterone. Before a FFTP the breast has few progesterone 
receptors and therefore, during the normal menstrual cycles the breast is 
stimulated largely by estrogens. FFTP somehow results in the increased 
development of progesterone receptors so that after the first birth, normal 
14 
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cycles results in adequate stimulation of the mammary ductal cells by 
progesterone^ cellular differentiation and a consequent reduction in risk of 
breast cancer. 
The observation that the early part of a women's first pregnancy differs 
endocrinologically from the second pregnancy was also stated by Bernstein 
et al. (1986). The level of estrogens differs in nuUiparous and parous women 
(Bernstein et al, 1985). The level of PRL was also found to be lower in parous 
as compared to nulliparous women (Yu et al, 1981). In other words increase 
parity is significantly associated with decrease amount of PRL (Burning 
et al, 1983; Wang et al, 1987). 
Obesity increases the risk of breast cancer in post menopausal women 
(Henderson et al, 1984; Boyle and Leake, 1988), the opposite may be true 
for breast cancer occuring in premenopausal women (Willett et al, 1985; 
Kampert et al, 1988; Trelti S, 1989). In the former, this could be either due 
to effect exerted by estrogen aromatized from androgenic prohormones in 
adipose tissue (Siiteri PK, 1987) or due to energy rich diet (Dewaard and 
Trichopolous, 1988). Also high fat diet causes elevation of plasma PRL 
concentration (Hill et al, 1980) the suggestion has been made that the 
tumourigenic effects of high fet diets are mediated through actions of PRL. 
15 
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2.3 BREAST CANCER AND STEROIDS 
2.3.1 ESTROGENS 
As breast cancer was considered to be hormone dependent from the 
beginning of the last century (Boyd S., 1900), it was assumed theoretically, 
in such a case, mammary gland will progress from its normal growth to 
hyperplasia to neoplasia as a consequence to the proliferative effects of the 
particular hormone. As a result, a major role of estrogen and other hormones 
in the etiology of breast cancer was emphasised. 
Earlier reproductive stage of a woman was considered to predict course 
of hormonal therapy to treat a women with this malignancy but only one third 
of the patients responded to endocrine therapy, thus till the end of seventies 
there had been no reliable way to predict the type of tumours that were 
hormone dependent without the actual trial. 
Estrogen receptors were reported in human breast carcinomas by using 
radioactive estrogen for binding to these specimens (Jenson et al., 1967). The 
binding of estrogens were found to be present in higher concentration in 
cytosolic fraction of human mammary cancer cells (Korenman and Dukes, 
1970) and was considered to be prerequisite for hormonal stimulability of 
breast cancer. With these findings, studies were performed to understand the 
mechanism of hormones interaction with the target tissue (Jenson and 
DeSombre, 1972). The initial step in hormone actions was found to be the 
binding of the hormone to highly specialized receptor protein that initiates a 
series of biochemical steps and eventually leads to a alteration in cellular 
metabolism or growth. 
16 
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The importance of receptor studies in recommending hormonal therapy 
to breast cancer patients was emphasised as these were the main biological 
factors which were responsible for the intracellular accumulation of estrogen 
in normal estrogen target tissues and certain breast cancers. Presence of 
estrogen receptor (ER) gave an idea that tumour was hormone dependent 
while absence of this receptor would make the cell devoid of estrogenic 
activity thus making it hormone independent. Since then estrogen receptor 
assay has become important in the clinical assessment of breast cancer 
(WittHff, J.L. 1984). 
The clinical parameters such as age and menopausal status was corre-
lated with the presence of ER .. Olden women or post menopausal women 
were more likely to be ER positive and contain a higher ER concentration 
(Clark et al, 1984). Post menopausal women at high risk for recurrent disease 
demonstrated that the natural course of the disease is significantly better for 
ER positive then ER negative patients. (Thorpe et al, 1986).Primary tumours 
were more hormone dependent than the secondary tumours i.e. histological 
features which differentiate into poor pathological conditions were estrogen 
receptor negative (Vihko et al, 1980). However, in other study no such relation 
could be observed (Brdai et al, 1988). The pregnant women with ER negative 
tumours had poor prognosis (Holdaway et ai, 1984) whereas lactating 
women usually have ER positive tumours that are responsive to hormonal 
therapy. 
Data from study of Crows et al. (1986) suggested that the relationship 
between ER content of a tumour and obesity to predict the prognosis appears 
to be related to the breast cancer stage and patient race. Black patients with 
ER negative tumours during postmenopausal stage have poor prognosis. 
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2.3.2. PROGESTERONE 
It is reported that not all patients with ER positive tumours respond to 
hormonal therapy. One possibility for this failure may be the defect in the 
intracellular cascade of events that normally controls the biological activity 
in response to endocrine stimulus. The determination of progesterone recep-
tor (PgR) in breast tumours might assess intactness of the estrogen response 
mechanism as estrogen exerts its biological effect through the formation of 
PgR both in normal as well as in neoplastic cells. It was hypothesised that 
the presence of PgR in human breast tumour might be a sensitive marker for 
predicting the response to endocrine therapy as it will indicate both the 
presence of ER and that the biochemical steps after hormone receptor 
interaction are functional (Horwitz et al, 1975). 
A widely held view is that progesterone reduces the carcinogenic effects 
of estrogen. This view coincides with the earlier epidemiologic data that breast 
cancer risk is increased with the occurrence of early menarche and late 
menopause when the menstrual cycles may be anovulatory and estrogens are 
unopposed by progesterone. 
Progresterone inhibits estrogen action by suppressing its receptors in 
uterus (Hsueh et al, 1975). Another evidence in favour of progesterone 
having a protective role in breast cancer is that when exogenous estrogens 
are given to oophorectomised women, their breast cancer rates increased from 
those having ovaries (Hoover et al, 1976). 
Specific progesterone receptors in human breast cancer were reported 
(Horwitz and McGuire, 1975). Since PgR may be a better marker for tumour 
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endocrine dependence than ER, it was suspected that presence of PgR may be 
an important prediction of time to recurrence for patients who received 
adjuvant endocrine therapy for primary breast cancer. Breast cancer patients 
who having PgR comprise a group with a better prognosis (Pichon et ai, 
1980). Frequency of metastasis and disease free survival were inversely 
proportional to these receptors. In the study of Manson et al. (1983) though 
both ER and PgR status predicted overall survival in patients with or without 
nodal involvement, only PgR predicted prolonged disease free survival. Inspite 
of these and other studies, there were some findings which opposed the 
importance of progesterone as prognostic factor (Allegra et al, 1979; Stewart 
etal, 1983). 
Progesterone is also known to stimulate growth in breast tissue. How-
ever no abnormality in progesterone level was found in women with breast 
cancer (Malarkey et al, 1977a; Read et al, 1985) but late menarche and early 
menopause, which are associated with decreased risk also mean a net reduc-
tion in progesterone stimulation, implying that progesterone is co- car-
cinogen, enhancing the adverse effect of estrogens. 
2.3.3 ANDROGENS 
Androgen receptors (AR) may also act as marker for tumour differentia-
tion, though these receptors have been found in upto 35% to 50% of human 
breast cancer assayed (Ochi etal, 1978; Bryan et ai, 1984), there is some 
evidence that their presence may correlate with response to endocrine therapy 
and with patient survival. The data also suggests that the response to 
endocrine treatment of mammary tumours that are AR and ER positive is 
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higher compared with the mammary tumors that are positive for only one 
receptor (McGuire WL, 1977). 
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2.4 BREAST CANCER AND PROUCTIN 
In the past two decades there had been a large body of investigation in 
the PRL as a potentially important hormone in human breast tumorigenesis. 
Ben David etal (1981) in his studies on binding site for PRL reported a higher 
dependency of breast cancer on PRL than on steroid receptors. Much of the 
evidence for demonstration of its important role in developing mammary 
carcinoma had come from experimental data. Daily administration of PRL 
(Boot etal., 1962), induction of hypothalamic lesions which sharply in-
creases pituitary PRL release (Bumi and Montemurro., 1971) and grafting 
pituitaries in kidney capsule (Boot etal., 1962) led to higher incidence of 
mammary cancer in mice. In contrast, inhibiting the PRL level to less than 
normal, in ovarectomized mice by Bromoergocryptine, a drug, which inhibitis 
PRL secretion prevented the development of mammary cancer in mice (Welsch 
and Nagasawa, 1977). Pregnancy which elevates PRL levels enhances the 
growth of hormone dependent mammary tumours in rats (McCormick and 
Moon., 1965). 
The exact role of PRL in human mammary tumorigenesis is unknown 
although clinical studies have provided evidence suggesting responsiveness 
to suppression of this hormone in some cases of metastatic carcinoma of the 
breast (Murray etal, 1972; Minton JR, 1974). The beneficial effects of 
hypophysectomy in stage IV breast cancer patients who were treated with 
antiestrogens suggested the role of pituitary hormones in maintaining the growth 
of snrrip hujTiar! hrp?i<;t cpncers (Pp3r<;on ct n'l.^ 1078). These studies showed 
tumours dependency on PRL. However only a very small fraction of mammary 
tumour explants derived from 26 biopsy specimens of human breast tumours 
responded with inaeased DNA synthesis when PRL was added to insulin and 
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hydro- cortisone-enriched medium, as judged by increased in cooperation of 
H^-thymidine into DNA (Welsch et al, 1976), which suggested that a very 
small fraction of human breast malignancies may respond to the growth 
stimulating effect of PRL. It may be stated that an interrelationship between 
high levels of PRL and the incidence of breast cancer could be established in 
certain circumstancs (Simon et al., 1984) where mammary carcinoma cells 
are stimulated by PRL but not in others (L.' Hermite- Baleriaux et al, 1984). 
The studies designed to determine whether or not patients with breast 
cancer or benign disease have higher mean serum PRL levels have been 
conflicting and confusing, some workers have reported higher plasma PRL 
levels in breast cancer patients than in healthy controls (Murray et al., 1972; 
Rolandi et al, 1974) but others failed to find any correlation (Dicky and 
Minton., 1972; Boyns et al, 1973; Franks et al, 1974). 
The conflicting results obtained with serum PRL in epidemiological 
study might be due to the fact that its secretion varies according to age 
(Vekemans and Robyns, 1975), menstrual stage (Ehara et al, 1973; McNeilly 
and Chard, 1974), drug usage, time of day (Bulbrook et al, 1981) and 
emotional conditions. Also there is a problem in relating plasma PRL level 
with the risk factors in the pulsatile fashion of secretion exhibited by the 
hormone. It is thus difficult or almost impossible to exclude in clinical studies 
all or even part of these factors influencing human PRL, secretion and plasma 
levels, thus rendering an obstacle for the proper evaluation of the role of this 
hormone in breast cancer. 
22 
Review of Literature 
To overcome this in part preoperatively hourly serum PRL levels over a 
24 hrs. period in women with breast cancer were detennined and nocturnal 
PRL concentration was found to be significantly decreased in post menopausal 
breast cancer patients and significantly elevated in premenopausal women 
with breast cancer when compared to age and weight match control subjects^ 
(Malarkey et ah, 1977) but other workers have reported increased PRL levels 
in association with increased breast cancer in post- menopausal women (Kwa 
et al., 1981; Bonneterre et al, 1986). This increase in PRL level was found in 
subjects even 5 years prior to their clinical diagnosis of breast cancer was 
made. 
In the case of benign breast disease patient's basal PRL concentrations 
do not differ significantly from that of the controls (Boyns et al, 1973; 
Sitruk-Ware et al, 1979; Mansef et al, 1980). However when PRL level in 
serum samples taken daily throughout the menstrual cycle of patients with 
benign breast disease was estimatied it was found that plasma PRL levels was 
abnormally elevated, especially in women over the age of 30, indicating a 
possibility of involvement of PRL in this condition (Cole et al, 1977). The 
failure to get any difference in PRL level in patients and controls in the former 
studies might be due to the fact that these studies were based on single samples 
taken at random times in the menstrual cycle. Also basal serum PRL levels 
have also been reported marginally but significantly elevated in patients with 
cyclical mastalgia (Watt-Boolsen et al, 1981). It might be due to altered 
central regulation of PRL secretion and not caused by altered dopaminergic 
tone (Peters et al., 1981; Kumar et al, 1984). In other words, hypothalamic 
pituitary axis is not primarily disturbed in patients with cyclical mastalgia and 
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fibrocystic disease so as to cause PRL elevation. However, there is no evidence 
to suggest that patients v^ rith cyclical mastalgia have increased risk for breast 
cancer except when there is proliferative type of hyperplasia in the breast 
(Dupont and Page 1985). 
There are also some circumstantial evidence to implicate PRL in the 
aetiology of human breast cancer A full term pregnancy lowers the PRL 
concentration and this may explain the epidemiologic observation that early 
FFTP' lowers breast cancer risk (MacMohan et al, 1973). Other workers also 
related the age of the woman at her first as well as last delivery with the cancer 
risk (Hunt et al., 1980; Kwa et al, 1981; Wang et al, 1985). Earlier is the 
event of last birth, greater is the risk e.g. five birth spread over 20 years would 
have more protective effect than if those births were spread over 5 years. This 
could be due to the fact that protective environment of lowered PRL level 
caused by deliveries in premenopausal women with increasing parity is 
transitory. After the last delivery PRL level rises as the time elapses. 
Musey et al. (1987) concluded in their study that (1) a first pregnancy 
causes a significant decrease in basal levels of serum PRL and a significant 
decrease in pituitary secretory capacity for PRL, (2) this effect occurs after 
both an early and late first pregnancy, (3) these are long term changes lasting 
at least 19 months for the depression of PRL secretory capacity and at least 
12 to 13 years for the depression of basal PRL levels, (4) these changes are 
not related to age, (5) there are no corresponding changes in basal levels of 
LH or FSH or in the pituitary secretory capacity for LH & FSH. 
The level of PRL is also affected if a patient has a family history of breast 
cancer Kwa et al. (1974) were the first to demonstrate elevated PRL levels in 
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patients with a family history of the disease. The differences in PRL levels 
between daughters of cancer patients and that of control were significant only 
when other hormones, estrone plus estradiol, were considered together with 
PRL (Henderson et ah, 1975; Trichopoulous et al, 1981) and not otherwise 
(Fishman et al, 1978). At the luteal phase when both estradiol and 
progesterone levels were highei; an abnormal evening peak of PRL levels were 
found in women with a history of cancer (Kwa and Wang, 1977). It was also 
stated that other risk factors of breast cancer such as nulliparity may be linked 
with higher evening PRL level (Kwa et al., 1978). 
Radical mastectomy in patients with breast cancer was followed by 
hyperprolactinemia which was normalised at 3-12 months postoperatively 
(Bami et al., 1987). Authors related the elevated PRL level with the metastasis 
and estrogen receptors positivity. According to them, the percentage of cases 
with hyperprolactinemia induced by mastectomy was significantly higher in 
patients without node involvement compared with those with axillary node 
involvement (12/17 Vs 6/17; p). Also, the percentage of hyperprolactinemia 
was higher in negative estrogen receptor patients than in those with positive 
receptors (10/13 Vs. 8/21; p). 
The evevated PRL either preoperative and/or post operative were 
significantly correlated to survival, in all cases, the least favourable prognosis 
was associated with highest PRL levels (Wang et al, 1986). Similar findings 
were oDserved by Dovvserr et al I^IVSJ; and by Holtkamp et al (1984}. The 
higher the PRL level prior to treatment, the less probability of response to 
endocrine treatment or even chemotherapy It was also the obseivation of 
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Holtkamp et al (1984) that hyperprolactinaemic patients experiencing remis-
sion after chemotherapy exhibited a return of their PRL leves to normal. In 
spite of the poor prognosis of patients with hyperprolactnaemia^ remission 
were achieved with chemo or hormonal therapy in some patients, but it 
remains to be established in which patients PRL inhibitors are of therapeutic 
value. 
The inability to demonstrate elevated PRL levels in patients with breast 
cancer in some studies does not rule out the possible importance of PRL in 
the pathogenesis of breast cancer or the possible usefulness of its suppression 
in therapy. As PRL plasma level were of poor value to study the PRL sensitivity 
of human breast cancer and assuming that PRL stimulates human breast 
tumour, the tumoral tissue should contain PRL receptors. In vitro studies on 
human breast cancer cells suggest that specific PRL receptors are present in 
some lines (MCF-7), and increased synthesis of estrogen receptor content has 
also been reported in tumour cell line MCP-7 by PRL (Shafie & Brook 1977). 
Physiological concentration of PRL were showed to promote the growth of 
breast tumour cells in culture (Malarkey et al, 1983; Manni et al, 1985) by 
acting at the level of gene expression, synthesising three unique proteins in 
the PRL receptor positive human breast cancer cell line (Shiu and Iwasiow, 
1985). Since PRL facilitates the growth of human breast cancer cell lines, 
these results suggest that many human breast cancer may be PRL dependent. 
In the last few years several reports (Turcot-Lemay et al, 1982; Di Carlo 
et al, 19S3. Murphy et al. 198'1: L. Hermite Baleriaux ct al, 1987} stated 
the presence of low but measurable levels of PRL-R in both benign and 
malignant human tumours. Though the role of PRL in the development of 
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human breast cancer is less well established (Costlow and Mc Guire 1978), 
yet specific binding of hviman PRL of greater than 1% was seen in 20% of 
breast tumours. Binding capacity for PRL in pre- menopausal patients was 
greater than that of the postmenopausal patient (Partridge and Hahnel 1979) 
but this study has not discussed the presence of endogenous PRL. A certain 
portion of the PRL receptors may be occupied by the endogenous circulating 
PRL. Since the bindning of PRL to its receptors is relatively stable, most of 
these receptors remain occupied after the homogenization and membrane 
fractionation procedure. Therefore these receptors remain undetected unless 
the bound PRL is removed. When the endogenous bound PRL was dissociated 
from its receptor by a short exposure to MgCb (in vitro) or CBI54 (in vivo) 
(Kelly et al, 1979), there is rise in percentage positivity of tumour from 49% 
to 71% (Peyrat et al, 1982). Bonnelerre et al. (1982) examined PRL-R on 
tumour plasma membrane. 
The physiological concentration of PRL could promote the growth as 
well as DNA synthesis of human breast cancer cells in 29% of the cases through 
these receptors. In the absence of PRL the stimulation of DNA synthesis did 
not occur (Peyrat et al, 1984). It was reported that women with breast cancer 
patients having tumours with high PRL-R have poor prognosis (Waseda 
et al, 1985) but this was later contradicted (BonneteiTe et al, 1986). 
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2.5 HORMONAL MANIPULATION 
Breast disease, as discussed previously is mostly hormone dependent and 
therefore its course could also be influenced favourably or unfavourably by 
hormonal manipulation. George Beatson (1896) introduced tumour regres-
sion in patients with breast cancer by Oophorectomy, but the failure of 
response to oophorectomy in some patients was due to the continued secretion 
of estrogens by the adrenal gland»Huggins and Bergenstal (1952) introduced 
adrenalectomy as a successful means of postmenopausal endocrine ablation 
in advanced breast cancer 
Metastatic breast carcinoma in one patient regressed when hypophysec-
tomy and termination of pregnancy was done (Barett et at., 1975). Pituitary 
ablation may decrease tumour growth by removing F'RL & GH. Adrenalec-
tomy and hypophysectomy are thought to affect breast cancer by ablating all 
adrenal function, thus removing the last remaining source of androgens that 
can be converted to estrogen in post menopausal women. However, 
hypophysectomy was shown to be more effective than adrenalectomy. But as 
both procedures result in high morbidity and mortality, they are not used 
frequently. 
Other approach to honnonal therapy was the use of antiestrogens that 
antagonize estrogen effects. Their main characteristic is blocking the uptake 
uf e-''"adiwi in V-r.rh rvpc .^riir.cntal ZT.d. hum.an tumours. Tamoxifen, ? 
triphenylethylene antiestrogen^ enjoys wide clinical usage. As low levels 
of estrogen production and excretion remain even after oophorectomy 
adrenalectomy and hypophysectomy, tamoxifen was used to antagonize this 
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estrogen effect. With this both early as well as advanced breast cancers could 
be treated and also survival v/as prolonged in some cases (Baum et al., 1983). 
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2.6 RELATIONSHIP BETWEEN ESTROGEN, 
PROGESTERONE AND PROLACTIN RECEPTOR 
Relationship between PRL-R and steroid receptors are suggested in 
literature. Bonneterre et al. (1986) showed that a statistically correlation 
existed between ER and PgR, between ER and total PRL-R or free PRL-R, and 
between PgR and total or free PRL-R. This had been suggested by Holdaway 
and Friesen (1977) and confirmed by Murphy et al (1984) for cell lines as 
well as for mammary cancer. Partridge and Hahnel (1979) found that the 
affinity of PRL-R was higher in ER positive tumours. Conversely neither Vihko 
et al. (1980) nor Waseda et al. (1985) found a relationship between PRL-R 
and steroid receptors. There is a complex "interplay" between the three 
hormones, viz. estrogen, progesterone and PRL (Table 2.2). All the three 
hormones induces the appearance of each other's receptors. It may therefore 
be inferred that no single hormone can be responsible for pathological lesions 
seen in the breast. 
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Table 2.2 Hormone interaction in breast-estrogen, 
progesterone & prolactin 
a. Estrogen 
— stimulate proliferation of ductal epithelium (Portei; 1974) 
— stimulate PRL secretion from anterior pituitary. (Miller et ah, 1977) 
— increase PRL receptors in breast (Sheth et al., 1978) 
— induced progesterone receptors (Horwitz & McGuire, 1978) 
— suppress LH/FSH secretion (Yen et al, 1975). 
b. Progesterone 
— stimulate proliferation of terminal duct lobular unit (Porter, 1974) 
— inhibits PRL secretion by increasing dopamine secretion. 
— inhibits lactation during pregnancy (Davis et al, 1972) 
— inhibits estrogen receptors in uterus (Hsueh et al., 1975) 
— facilitates estradiol inactivation (Tseng & Guipide, 1975). 
c. Prolactin 
— stimulates lactation (Kandon et ai, 1983) 
— stimulates mammary cell division (Malarkey et al, 1983) 
— stimulates hypothalamic dopamine production (Peter et al, 1982) 
— stimulates its own receptors (Posner et al, 1975) 
— stimulates estrogen receptors in breast (Shafie & Brooks, 1977) 
— inhibits granulosa and luteal cell E2 and progesterone secretion. 
(McNatty et d., 1974). 
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2.7 PROLACTIN 
2.7.1 HISTORY 
PRL was identified in 1928 as a substance in anterior pituitary extract 
capable of causing lactation in pseudopregnant rabbit (Strieker and Grueter 
1928), though extensive physiologic and chemical studies was carried out on 
PRL from different animal species, its recognition as a separate hormone in 
man could not be achieved for the next 40 years. The reason was its close 
resemblance with GH which is about 100 times the amount of PRL in human 
pituitaries, and interfere with its separation procedure and obscured detection 
of the smaller amount of PRL. Later its independent identity was recognised 
in human blood and it was observed that despite their chemical and biological 
similarity, hPRL and hGH were quite distinct immunologically, with no overlap 
in immunological reactivity (Frantz and Kleinberg et al, 1970). With this 
finding more sensitive bioassays were developed and Guyda and Friesen 
(1971) succeded in separating out human and primate PRL from GH. In the 
following year Hwang etal. (1971) isolated small amount of primate PRL 
from pituitary extract and developed a radioimmunoassay for human PRL for 
measuring its concentration in sera at different age and at different stages. 
They also came out with an unexpected finding that amniotic fluid concentra-
tions of PRL were about 5-10 fold higher than the mother serum concentra-
tion. 
TiiL is secrcred hy mammcrrcphs cells that belong to acidophil celi^ -
series of pituitary (Halmi et al, 1975). It was found that two forms of PRL 
electrophoretically separable and having different bioassay and radioim-
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munoassay activities, were secreted by rat adeno-hypophysis 
(Asawaroengchai etal, 1978). Different forms of PRL were prsent in the 
circiolation at different times which differ from each another in biological and 
immimological potencies (Owens ct al, 1985). 
Structural changes in PRL occur also in women during, pregnancy and 
the menstrual cycle which are probably influenced by the hormonal environ-
ment (Larrea et al, 1989). Four PRL related monomers were characterised in 
humans pituitary homogenate having molecular weight 25,000 D, 29,000 D, 
45,000 D and 16000 D (Meuris et al, 1983). Lewis UL (1984) studied these 
variant and their post translational modifications. Frawley etal (1986) 
demonstrated that not only the hormone differ from each another in biological 
and immunological potencies but also their releaser cells. Some cells secrete 
PRL with extremely high biopotency and very low immunoreactivity whereas 
the converse is true for other cells. 
2.7.2 STRUCTURE 
Human PRL having molecular weight of 22,000-23,000 D is generally 
a single polypeptide chain consisting of 198 amino acid residues. It has stable 
three dimensional structure which is important for its biological activities 
including its interaction with the receptors. PRL was crystallised by Bell 
et al (1985) for analysing its structure by X-ray diffraction. 
Human PRL has more marked amino acid homology with bovine PRL 
than the ovine PRL. Its complete amino acid sequence was examined by Shome 
and Parlow (1977). The end group analysis of human PRL showed a single 
amino acid terminal residue, leucine in high yield confirming its homogenicity 
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(Hwang et al, 1972). It contains two tryptophan residues and six half cystine 
comprising three disulphide bridges. It has double the number of methonine 
residues as compared to rabbit PRL, but nearly half as that of ovine's. It is 
somewhat less negatively charged than either ovine PRL or human growth 
hormone with an isoelectric point of 6.5 or slightly less (Hummel et al, 1975). 
2.7.3 SITES OF DETECTION 
PRL can be detected in high levels in plasma, amniotic fluid and milk 
but in low levels in cerebrospinal fluid, semen and urine. Substantial quan-
tities of PRL are found in human amniotic fluid ranging from 2-100 times the 
concentration in maternal serum (Fang and Kim 1975). PRL can also be easily 
detected from all samples of human milk whether from nursing mothers or 
patients with galactorrhea. PRL detected in urine in veiy low amounts are not 
useful from a clinical or diagnostic stand point as it undergoes considerable 
degradation before excretion into urine. 
2.7.4 ROLE 
PRL is a potent stimulator of lobuloalveolar proliferation of breast and 
of lactation. In rats it was found to be essential for the normal development 
and differentiation of the virgin female breast (Lyons et al, 1958). The growth 
of mammary glands in the hypophysectomized gonadectomized and 
adrenalectomized rats, in the presence of estrogens or estrogens in combina-
tion with other steroids were ineffective in inducing any significant degree of 
breast growth unless PRL was coadministered. Similar importance of PRL in 
human is unclear as the deficiency of PRL in human is veiy rare. Also rarely 
there is any sign of erJargement of breasts in cases of hyperprolactinemia 
conditions caused due to pituitary tumors in humans. Gynaecomastia patient 
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(Men with enlarged breasts) do not have elevated level of serum PRL (Frantz 
etal, 1972). These findings, however, do not rule out an essential role of 
PRL in the development of human breast cancer. 
PRL is an essential hormone both for the initiation and maintenance of 
lactation. Though other hormones are also required, the production of milk 
proteins is critically dependent on PRL (Topper YJ, 1990). There is increase 
in PRL level in blood steadily from early gestation till term. During the period 
of gestation PRL together with estrogens and progesterone further develops 
the lobulo-alveolar system of breast. At the time of parturition, levels of 
estrogen and progesterone are decreased due to expulsion of placenta. This 
decrease initiates the onset of lactation which is maintained by the suckling 
stimulus. The level of PRL remains high, but as time ceases it returns to the 
normal level. During lactation even when PRL levels are high, ovulation occurs 
(Hall etal., 1980). Oral administration of estrogen antagonises PRL for the 
lactation to take place. In many species including man, the excess secretion 
of PRL influences, stimulating and suppressing, the production of steroid 
hormones (Veldhuiset a/., 1980). It stimulates the production of estrogen 
receptors in the breast (Shafre and Brooks, 1977) but on the other hand it 
inhibits estrogen and progesterone secretion from the ovary (Mc Natty et al., 
1974). 
PRL together v^th insulin and hydrocrotisone stimulates fatty acid 
S3 .^th£3:s in mammary giands (Wang ^ ' ttai, 1972), irr its prei;t;nce i;hort 
chain (C) fatty acid while in its absence long chain fatty acids are synthesised. 
PRL also controls lipoprotein lipase activity in the mammary gland (Zinder 
35 
Review of Literature 
et al., 1974), as PRL can retain its activity in hypophysectomised lactating 
animals (Falconer and Fiddler 1970). It also promotes the active transport of 
ions out of the gland (Falconer and Rowe 1977). 
2.7.5 CONTROL OF SECRETION 
Data from various studies on animals and humans show that PRL 
secretion is under the control of hypothalamus and this action is rather 
inhibitory in nature via the secretion of PIF into the portal circulation. The 
variation of this factor in the portal blood causes the short term fluctuations 
in the secretion of the hormone. PIF is considered to be a neurotransmiter, 
dopamine or its constituents, as the latter also has an inhibitory effect on the 
hormone by acting directly on the specific dopaminergic receptors present in 
the pitutaries (Shaar and Clemenset, 1974; Takahara etal, 1974; Peters 
et al., 1982). Drugs that block dopaminergic receptors raise serum PRL in 
humans (Foord et al, 1983). 
Like the other peptide hormones, the PRL itself may inhibit its own 
secretion via a short feed back loop as it has no target organ inhibitory feed 
back system (Mac Leod and Lehninger, 1974). The stimulatory action of 
hypothalamus on PRL release is due to the presence of atleast two factors TRH 
and non TRH (PRF). Though TRH can directly stimulate pituitary PRL 
secretion in female and male subjects (Yuen et al, 1973), the response being 
significantly greater in the former than in the later (Jacobs et al, 1973), yet 
it is nor a physiolcgical rdeatcr ci Ciy- hormone (Reklilin, S., 1966, Cht^ n 
et al, 1970). TRH induced PRL release is not altered by pretreatment with 
estrogens or androgens (Yuen et al, 1973) or during pregnancy (Tyson and 
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Friesen, 1973). In addition to its direct action on pituitary cells, TRH also acts 
at the hypothalamic level to inhibit PIF secretion (Diefenbach et al, 1976). 
In females, administration of high doses of estrogen can increase PRL 
release (Yen et al, 1974) but apparently the amounts of estrogens secreted 
during the menstrual cycle are not sufficient to raise serum PRL level. 
However, the difference in estrogen among both the sexes in human accounts 
for the low level of basal PRL and no response to stimulation in men. Estrogen 
or estrogen contraceptives stimulate PRL-RNA synthesis by an independent 
mechanism than that of pituitary protein synthesis (ShuU & Gorski, 1984). 
Indirectly estrogens also increase the response of lactotrophs to TRH (Harper 
MJK, 1977). The interrelation between the two hormones is very complex as 
they at times synergise the action of each other(during breast development}^ 
while at other times, they oppose each other(during lactation^. 
Progesterone influence on PRL secretion is not fully defined in humans. 
However, it is the main inhibitor of lactation (Davis, et al, 1972). Androgens 
inhibit PRL binding as shown in rat livers (Kelly et al, 1977). 
2.7.6 PRL LEVEL AT DIFFERENT STAGES 
Secretion of PRL rises from the 25th week of gestation in the foetus till 
birth. After birth till puberty in girls there is no difference in PRL level between 
the two sexes. The rise in PRL levels in girls may be due to increase in estrogen 
level at puberty The PRL level in older women ^gradually declines till 
menopause and after the age of 65 its level is decreased due to reduction in 
ovarian stereogenesis. In post menopausal women, basal PRL levels are 
significantly lower than in premenopausal females. In contrast PRL levels in 
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men tend to increase after 45 years of age (Sarfaty et al., 1976; Vekemans and 
Robyns, 1975). 
PRL shows pulsatile secretion like the other pituitary hormones. Its level 
was found to be highest when the subject is asleep but not when it is awake 
(Sassin et al, 1972; Nokin et al, 1972). The night increase in PRL level is 
absent in pituitary tumours. In hyperprolactinemia it may be present or absent 
due to other causes. Stresses of all kinds, either physical or surgical increase 
the PRL level. 
During the menstrual cycle, the PRL levels are irregular and inconsistent 
(McNeilly and Chard, 1974) and most of the workers did not observe a 
significant variation in circulating PRL levels. However, PRL levels in the 
plasma were elevated during the luteal phase than during the follicular phase 
(Cole etal, 1977). Menstrual cycle disorders like amenorrhea, oligomenor-
rhea and luteal insufficiency are associated with excess of PRL secretion. 
Hyperprolactinemia interfere with gonadal function, thus causing infertility 
in humans. This is done by binding to the specific sites in the ovarian tissue 
(Ben David and Schenkei; 1982). 
In humans, there is a more or less steady rise of maternal serum PRL 
throughout gestation (Tyson etai, 1972). This progressive rise in pituitary 
PRL release is related to the relatively high estrogen secretion during this 
period. An intact mature hypothalamus is not necessar^ ^ for attainment of high 
plasma PRL levels at term since encephalic iiifants show plasma PRL level 
similar to healthy newborn. This is in contrast to the very low levels of GH, 
FSH, LH, TSH, ACTH in the umbilical cord blood of an encephalic new bom 
(Aubert et a/., 1977). 
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The suckling effect by the newly bom in the post partum mothers causes 
the maximum rise in the serum PRL levels (Noel et al., 1974; Schmidt-Gollwit-
zer and Saxena 1975). This effect could also cause rise in PRL levels in non 
lactating women (Kolodny et al., 1972). The rise in PRL level is maintained 
even after this period till the mother is nursing as higher PRL concentrations 
have been reported in lactating mothers even later than 13 week post partum 
(Rolland et al, 1975; Bonnar et al, 1975). 
Pharmacologic factors, e.g. dopaminergic antagonists, phenothiazines, 
butyrophenones, calecholamines depletors, synthesis inhibitors, increase PRL 
secretion whereas dopaminergic agonists like L-dopapomorphine and 
dopamine and bromocriptine suppress PRL secretion. 
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2B GLYCOPROTEIN HORMONE 
FSH and LH are secreted by anterior pituitary. They are termed as 
gonadotropins as they regulate gonadal functions. They control target cell 
function by modulating adenylate cyclase activity in their resepective target 
cells (Crooke et al, 1976). 
Molecular weight of these vary from 28,000-43,000 D. They are com-
posed of two non identical peptide chains alpha and beta, which are linked 
by hydrogen bonding and Vander Waal's forces. The alpha chains of both these 
hormones are identical in amino acid sequence, the beta chain of each is 
unique. This alpha chain possesses 96 amino acids and two complex moieties 
at amino acid positions 56 and 82. The carbohydrate moities are linked via 
asparagine and contain in order galactose, N-acetyl glucoamine, mannose and 
sialic acid. The beta chain of human FSH contains 115 amino acids and two 
asparagine linked carbohydrate moieties at position 7 and 24 whereas beta 
chain of LH contains complex carbohydrate moieties at different positions i.e. 
13 and 30. Complex feedback mechanism which involves participation of the 
target organs. The beta sub-chain of both the hormones are specific and bring 
about the biological function in conjunction with the alpha-subunit (Hall 
eta/., 1980). 
A decapeptide known as gonadotropin releasing hormone (GnRH) 
stimulates the pituitary to release these hormones. This GnRH is in turn 
controlled by a complex feedback mechanism mediated by estrogen and 
progesterone (ovarian steroids) tissue via the blood stream. LH/FSH secretion 
is low during the luteal phase of the cycle when the secretion of ovarian 
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estrogen and progesterone is maximal and increases again in the early 
follicular phase when ovarian hormones are low, thus demonstrating the 
negative control of GnRH and also of LH & FSH. At mid-cycle there is a sharp 
rise in the ovarian estrogen secretion due to the maturing follicle, there is a 
positive feedback stimulus to the hypothalamus and pituitary resulting in a 
surge of GnRH and LH, with some FSH, which leads to rupture of the follicle 
and ovum release. 
These hormones reach their target tissue via the blood stream in the free 
form. Administration of GnRH results in a increase serum LH levels within 
few mins., the peak level reaching in 20-30 mins. Baseline levels are restored 
6 hours after a dose of 100 ug of GnRH. The FSH response is similar but of 
lessor magnitude (Yen et al, 1975). 
The reports on the role of other neurotransmitters in regulating the 
gonadotropin secretion and secretion of GnRH from hypothalamus are con-
troversial (Krulich, L 1979). The evidence for the dopaminergic inhibition of 
LH is also clearcut but the action of several DA receptor agonists on LH 
secretion may not be similar (Martin et al., 1981). 
Pituitary and gonadal hormones have been evaluated in blood and urine 
respectively of women with benign cystic breast disease. In the cyst fluid, the 
level of LH and FSH were significantly lower as compared to PRL levels 
(Bradlow eta/., 1983). 
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2.9 PEPTIDE HORMONE RECEPTOR 
PRL being a peptide hormone appears to initiate its action by interacting 
with a specific receptor on the cell surface of the mammary epithelial cell. 
Since the PRL receptors (PRL-R) are obligatory for mediating some, if not all 
of the actions of the hormone, the receptors may be important in determining 
the sensitivity of the tissue to the hormone. The mode of action was first 
suggested by Turkington (1970) who showed that PRL covalently linked to 
Sepharose beads, is biologically active in mouse mammary epithelial cells and 
initiates its effect by an action on the cell membrane, as PRL Sepharose 
complexes presumably cannot enter the cell. Subsequent studies, howevei; 
suggested that the result might have been due to a slow release of PRL from 
the Sepharose beads. These findings were confirmed by Birkinshaw and 
Falconer (1972) by means of autoradiographic methods. Since then much 
information on PRL receptors in the rabbit and rat mammary gland and now 
recently in human mammary gland has accumulated. 
Involvement of lysine residues in the binding of ovine PRL and human 
GH to lactogenic receptor was shown (de la Llousa etal, 1985). lyrosyl 
residue (s) present on the receptor molecule is also important for the receptor 
ligand interaction as the receptor in rabbit mammary gland was inactivated 
when treated with N-Acetylimidazole (Mahajan and Ebner, 1986). 
The binding of the hormone to its specific receptor causes the formation 
of an intracellular messenger molecule which-then stimulates (or depresses) 
some characteristic biochemical; activity of the target tissue. For the water 
soluble hormones, for example, peptide hormones, the cyclic nucleotides and 
Ca (and other ions) have emerged as the two main types of secondary 
42 
Review of Literature 
messenger molecules for commimicating between the cell surface and the 
intracellular metabolic machinery. Cyclic AMP is formed from MgATP ' via the 
membrane localised enzyme adenylate cyclase. The cyclic AMP breakdown is 
regulated by membranal and cytoplasmic phosphodiesterases. In keeping with 
its ubiquitous and important nature, the ligand receptor cyclic AMP system 
may be regulated at a variety of levels including stimulation and inhibition of 
both adenylate cyclase and phosphodiesterase. 
2.9.1 PRL-RECEPTOR MECHANISM 
As discussed previously PRL receptors (Mol wt. 41-49 KDa) are enriched 
in plasma membrane fraction derived from pregnant and lactating rabbit 
mammary glands (Shiu and Friesen, 1974). The highest levels occur during 
the lactational period in the rabbit (Djiane etal, 1977) and rat (Holcomb 
etal, 1976). Self induction of PRL receptors by PRL is indicated by the 
observation that receptor content increases after parturition. This increase is 
abolished when suckling is prevented or with administration of ergocomine, 
an inhibitor of PRL secretion (Bohnet et aL, 1977). The two major hormones 
which modulate the actions of PRL are glucocorticoids which are synergistic 
to most actions of PRL and progesterone which is the major inhibitor of PRCs 
action (Fig. 2.2). 
In the differentiated mammary gland that are being primed by insulin 
and Cortisol, PRL can stimulate the synthesis of milk proteins, the first or the 
essential step being the bindng of the hormone to its receptors. 
Unlike that of most polypeptide hormones, PRIs binding to the cell 
membrane receptor does not lead to the activation of the membrane bound 
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Fig 2.2: Schematic representation showing the events that takes 
place as PRL enters the mainmary cell. As PRL enters 
the cell through PRL receptor. 
i) Stimulation of mitotic activity takes place. 
ii) An activation of transcription of milk protein 
gene occurs. 
iii) The transcriptional products (in RNA) are 
stabilized. 
iv) Translation of messenger RNA is stimulated. 
PRL 
synergenized 
Progesterone 
antagonized 
Fig.2.2: Schematic representation showing the events that 
take place as PRL enters the mammary cells 
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enzyme adenylate cyclase. Furthermore, neither exogenous adenosine 3'-5'-
cyclic monophosphate (cAMP) nor its analong N -2'-0-dibutyryl cAMP 
mimics the action of PRL in the marmnary gland explants maintained in organ 
culture (Majumdar et d., 1971). Rillema and Wild (1977) showed that PRL 
at smaller concentrations, for example ug ml" concentration range was able 
to stimulate membrane associated phospholipase A to release [ H]-
arachidonic acid from phosphatidyl choline. They thus associated the binding 
of PRL to its receptor and the activation of this membrane associated enzyme 
with the milk protein synthesis (ReUima JA, 1975). 
Indomethacin, an inhibitor of prostaglandins synthesis blocks the 
stimulating effect of PRL. Studies on explants of mouse mammary gland in 
organ culture suggest that PRL stimulates the transcription of ribosomal RNA 
and the accumulation of messenger RNA for casein and alpha lactalbumin 
synthesis (Turkington et al, 1973). The action of PRL on milk protein 
synthesis (casein) may in part be mediated by polyamines. This is because 
PRL stimulates the activity of ornithine decarboxylase •• an enzyme involved 
in the pathway of polyamines biosynthesis (Oka and Perry, 1976). PRL may 
also stimulate the lactose synthetase system, the enzyme responsible for the 
formation of lactose, in the mammary gland (Turkington et al, 1968). 
The PRL receptor molecule has been purified (Haeuptle et al., 1983; 
Sakai et al, 1986) and antibodies have been raised to the antigen. Antirecep-
tor antibodies v/cre able ic bleck FRl acLi'jn on niilk protein synflicsis (Dji--"'-
et al, 1985). Antibodies raised in goats, of sow PRL receptor inhibit PRL 
binding to its receptors in several organs of various species. This suggests that 
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PRL receptors shared numerous antigenic similarities between species located 
on the part of the molecule that is chiefly involved in recognition of the 
hormone. Monoclonal antibodies to the PRl receptor have also been prepared 
(Djiane et a/., 1985). 
2.9.2 LH AND FSH RECEPTORS 
The endocrine control exerted by glycoprotein hormone upon the 
respective target cells is made possible by specific cellular receptors located 
on the cell surface. When bound to hormone, the receptor-complex activates 
the enzyme adenyl cyclase (Rodbell M, 1980) leading to the production of the 
'second messenger', adenosine 3'5' cyclic monophosphate (cAMP), and 
stimulation of intracellular metabolic events. 
FSH receptors from seminiferous epithelial cells of immature male rats 
have been reported to bind FSH with high affinity. Rat granulosa cells also 
contain specific FSH receptors (Means AR, 1975). A protein component and 
phospholipid present on the receptor, are important for receptor activity. Its 
molecular weight is 146,000 D. Binding was found to be temperature depend-
ent, optimal binding was observed at 24°C (Abou-Issa and Reichart, 1977). 
The LH receptors are obtained from testicular or ovarian homogenates 
by extraction with non-ionic detergents, Triton x - 100 (Dufau ML and Catt 
KL, 1976). Maximal binding was obtained at 24^C (pH 7.4). Molecular weight 
of the receptor by SDS PAGE was found to be 90,000 D but the naturally 
existing receptor is in dimeric form with a molecular weight of 200,000 D. 
Similar in case of FSH receptor, a protein component and phospholipids are 
essential for normal receptor activity suggesting it to be a glycoprotein (Dufau 
era/., 1973). 
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GnRH or LH-RH that controls the secretion of LH and FSH from anterior 
pituitary has its receptors on the membranes of target cell such as luteotrophic 
cells. A number of studies have reported that analogues of LH-RH are useful 
for the treatment of hormone-dependent breast cancer (Klign et al., 1985; 
Miller et al, 1985; Butzow et al, 1987), both in pre and post menopausal 
women. Although the antitumour effect of LH-RH analogues is thought to be 
primarily a result of estrogen deficiency, a detailed correlation of objective 
response by breast cancer patients treated with LH-RH analogues has not been 
conducted (Plovmian et al, 1986). 
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OBJECTIVES AND PLAN OF WORK 
Human breast is generally considered to be a passive organ being a 
'target tissue' for both steroids (estrogen and progesterone) and peptide (PRL, 
GH etc.) hormones. It was reported that even in the absence of lactation there 
is marked rise in serum PRL when female breast are mechanically stimulated 
(Kolodny et al., 1972). However, in another study gentle palpation of breasts 
or stimulation of nipples for 10 seconds was not associated with appreciable 
rise in blood PRL levels (Peters et al, 1982). Further reproductive disturban-
ces reported after mastectomy in goats raised the question as to whether 
human breasts were acting as endocrine organs (Diamond et al., 1982). 
Changes in breast epithelium and stroma are seen with the hormonal changes 
of the menstrual cycle. Alteration in the hypothalamic-pituitaiy axis function 
have been demonstrated in patients with benign disease (Kumar et ai, 
1984a&b). It is unknown, however, whether the anterior pituitary hormones 
have any direct action on the breast tissue. Since the breast cells were shown 
to possess specific binding sites for estrogen and progesteron (McGuire 
et al, 1977), the effect of LH and FSH on the breast tissue may be through 
their effect on the ovarian secretion. PRL is known to affect the milk secretion 
but the effect of FSH & LH is unknown in breast. 
The aim of this study, therefore, is to see if there is any specific binding 
sites for the peptide hormone (PRL, LH, FSH) in normal and pathological 
breast tissue. 
With this aim, the main objectives of the present study were-
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i) to determine the peptide hormone binding sites in human breast 
tissue slices using a highly sensitive immunocytochemical 
localization technique. 
ii) to determine if there are any functional conrelation between the 
hormone binding and the breast. 
iii) to identiiy 'high risk' changes in the benign breast tissue by 
reterospective and prospective staining of the breast tissue. 
iv) 10 demonstrate PRL binding sires in fine needle aspirate cytol-
ogy 
The binding was accomplished using DNP hapten sandwich staining 
(DHSS) procedure of Jasani etal. (1981). The second antibody used were 
labelled with hapten DNP and a monoclonal antihapten antibody was incor-
porated as a bridge between the primary antibody and the enzyme system. 
The colour reaction was developed using diaminobenzidine in the presence 
of nacent hydrogen peroxide generated by glucose oxidase in the presence of 
added glucose (Fig. 3.1). 
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Glucose 
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Fig. 3 .1 : Schematic representation of DNP-Lo-calisation 
System - their mode of interaction 
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INTRODUCTION 
Out of the various approaches for studying hormonal binding sites in a 
tissue immunocytochemistry is potentially of great interest. A tumour may 
consist of a mixture of positive and negative cells for peptide binding sites. 
Since, the biochemical technique requires tissue homogenization, this techni-
que is not able to distinguish between the two types of cells. Autoradiography, 
on other hand, requires use of radioactive material. Immunocytochemistry 
could identiy these cells by means of a specific antigen-antibody reaction 
rendered visible by a suitable marker. Keeping this in view a detailed study of 
immunocytochemically localising the peptide hormone mainly the PRL bind-
ing sites in various breast lesions was undertaken. Such a finding will open 
gates for a large number of experimentation and treatment for breast disease. 
Immunocytochemically demonstrable PRL Immunoperoxidase techni-
ques for visualising PRL, human GH, human placental lactogen in human 
breast cancer tissue using an antibody bridge technique (de Souza et ah, 
1977) replaced the autoradiographical techniques of localising the binding 
sites (Birkinshaw and Falconet; 1972, Rajaniemi et al., 1974). The technique 
demonstrated the apparent presence oi both PRL binding sites and en-
dogenous immunoreactive PRL in lactating mammary gland alveolar cells of 
rat suggesting.the presence of PRL receptors also within the cytoplasm, under 
physiologic condition, in addition to the cell membrane (Nolin and Witorch, 
1976). 
Using immunocytochemical techniques hormone binding sites in tissues 
other than the breast i.e. PRL, FSH, LH and GH in prostrate (Sibley et al, 
52 
Introduction 
1981), PRL & 24K protein sites in secretory endometrium (Mary et al, 1986) 
and gonadotrophic and PRL binding sites in normal and neoplastic ovaries (Al 
Tumimi et al., 1986) was also demonstrated. 
The presence of PRL has been demonstrated in benign and cancerous 
breast tissue sections using an immunocj^ochemical approach (Pumell et al., 
1982; Dhadly and Walkei; 1983). Out of the various fixative explored for 
immunocytochemistiy to examine the effect of these on the PRL receptors, 
formalin fixed tissue was found to be the most suitable (Salih et al, 1979). It 
has also been traced in different experimental conditions such as in cryostat 
sections and cell suspensions of breast cancer (Marchetti et al, 1984) and also 
in cancer cells in tissue cultre (Patterson etal, 1982), exploiting the im-
munocj^ochemical techniques. 
Detection of the PRL positive benign and malignant tumours could 
probably suggest the importance of PRL as a growth factor for these tumours 
and give further support to the use of anti PRL drugs in the therapy of the 
disease. 
Besides applying immunocytochemistry on the tissue sections for locahs-
ing PRL binding sites in breast lesions an attempt was made to localise these 
sites in fine needle aspirate also (FNA). By this method the cells are obtained 
by a small gauge needle generally with a vacuum system provided by an 
airtight syringe from any part of the body This technique, now popularly used 
as the diagnostic tool, offers several advantages over the use of surgical 
biopsies for hormonal receptor studies. It is relatively easy, cost effective and 
non-traumatic procedure as compared to surgical biopsy that provides tissue 
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for hormonal studies. In cases where surgery is not possible this is the only 
suitable method for such studies. 
Immunoperoxidase technique has already been utilized to study ER 
(Flowers etal, 1986; Masood S., 1989) and PgR (Lozwski etal, 1990) in 
FNA smears of patients with breast cancer as enough cells for demonstrating 
the receptors could be obtained by this technique. Howevei; studies on the 
PRL binding in c)^ology specimens of breast tissue is Wtherto undescribed. 
An initial attempt has also been made to determined whether breast has 
any binding sites for FSH and LH in benign and malignant condition. 
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A. PEPTIDE HORMONE BINDING SITES IN PARAFFIN 
SECTIONS 
MATERIALS AND METHODS 
MATERIALS 
Patients with benign and malignant breast conditions were studied 
clinically and histologically. A detailed history was taken and physical ex-
aniination was done in all the patients. Age, onset of symptoms and progress 
of the symptoms was recorded in all the patients. Fresh breast tissues were 
collected in formalin from operation theatres and processed to prepare the 
slides for histology. Paraffin embedded sections of about 5/^m thickness were 
cut and picked up on gelatinized slides. Both histochemical and im-
munocytochemical studies were done on these slides. Also retrospective breast 
tissue sections comprising of both benign and malignant conditions were 
included in this study. 
Immunocytochemical localisation of PRL, FSH and LH binding sites were 
carried out using a highly sensitive immunocytochemical method, the 
dinitrophenyl hapten sandwich staining procedure. It represents a novel 
versatile, indirect immunoperoxidase bridge technique designed for the detec-
tion of unlabelled primary rabbit antibodies reacted with antigen present in 
the sections or smears. 
The histopathological type of tissue selected for localising the three 
peptide hormone binding sites are listed in Table 3.1. Benign breast disease 
were classified into iwu groups - i) Kon proliferative lesions and ii) prolifera-
tive lesions (Dupont and Page, 1985). 
Materials & Methods 
The primary antisera used in this study were rabbit antihuman PRL, 
rabbit antihuman FSH and rabbbit antihuman LH hormone. These as well as 
secondary detection reagent kits were obtained from Biochemical Services 
Ltd., PO Box 129, Cardiff CF44'AI, U.K. BSA (A-8022), 3,3-Diaminobenedine 
tetrahydrochloride (DAB) (D- 5637) and glucose (G-5250) were purchased 
from Sigma Chemical Corporation (USA). All the other chemicals and 
reagents were of the highest purity available. 
Table 3.1 
BREAST LESIONS STUDIED FOR LOCALISING PRL, FSH AND LH 
BINDING SITES. 
Breast Lesion 
1. Malignant 
2. Non-proliferative 
3. Proliferative 
4. Lactating adenoma 
5. Gynecomastia 
PRL 
40 
50 
7 
2 
8 
107 
, 1 
FSH 
15 
14 
3 
1 
2 
35 
LH 
10 
12 
3 
1 
2 
28 j 
METHODS 
Five fim thick sections cut from the breast tissue, pituitary gland and 
lymph node were picked upon gelatinised slides (15% gelatin solution was 
smeared on the slides and these slides were kept at 40°C overnight for proper 
setting of gelatin). In each case routine haemotoxylin and eosin staining was 
carried out along with immunocytochemical method for histopathological 
diagnosis. Immunoc>icchcmicai siainmg v/as carried our in several batches 
consisting of 8-10 slides. Each batch included a section of ,pituitaiy and a 
section of lymph node. 
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Dewaxing of paraffin section was done by treating the slides with below 
mentioned reagents. 
Haemotoxylin-Eosin staining technique 
• Deparaffinised sections were washed with running water. 
• Sections were stained in a solution of haemotoxylin for 2-5 mins. for 
nuclear staining. 
• Washed in water till the section was blueing. 
• Decolourised with a solution of acidic alcohol (1%) till the cytoplasmic 
staining by haemotoxylin was removed. 
• Washedinnmningtap waterfor 5 to 15 mins. 
• Counterstained in 1% aqueos eosin for 1 min. 
• Washed rapidly in water and blotted. 
• Dehydrated in several changes of absolute alcohol. 
• Cleared in xylol and mounted in Canada Balsam. 
fmmunocytochemical staining technique 
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i) Inhibition of Endogenous peroxidase: For this purpose 
pre-incubation of deparaffinised sectioiu; was done in methanol 
containing hydrogen-peroxide. The slides were immersed into 
a mixture of 47.2 ml of methanol and 0.8 ml of 33% hydrogen 
peroxide for 30 minutes at R.T.CStreefkerk, 1972). 
ii) Rehydration: Slides were washed by immersing them into 
distilled v^ a^ter for 2 minutes x 3 changes. SUdes were then 
transferred in ajar containing PBS (0.01 M, pH=7.1) for 2 mins 
X 3 changes. 
After these steps, dinitrophenyl locaHsation system was used for 
detecting primary antigenic sites. 
iii) Incubation in primary antibody : The primary antibody 
was applied at the optimum dilution (dilution profile experi-
ment was carried out for each antibody to evaluate the ap-
propriate dilution). PRL was applied at dilution 1:15,000, FSH 
at 1:10,000 and LH at 1:7,000. The dilution was done with 
0.6% BSA in PBS. The slides were covered with either of the 
required primary antibody (50 ul to 100 ul) and left overnight 
at 4''C in a closed moistened box. 
iv) Washing in PBS was conducted by total immersion of the sHdes 
in a coplin jar (1 min. x 3 changes). 
v) Incubation in excess of second antibody labelled with DNP was 
for 30 mins. at R.T. The second antibody used here was antirab-
bit IgG tagged with DNP 
vi) Washing in PBS as in step iv. 
vii) Incubation in IgM anti DNP bridge antibody was achieved by 
applying 50 ul uto 100 ul of a 1:500 dilution of hybridoma asate 
fluid 10 the slides for 30 mins. ai Fv.T. 
viii) Washing in PBS as in step iv 
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ix) Incubation in DNP peroxidase conjugate in dilution 1:800 of a 
standard preparation for 30 mins. at RT. 
x) Washing in PBS as in step iv. 
xi) Incubation in DNP glucose oxidase (100 units/ml solution) for 
generation of nacent oxygen (50 ul to 100 ul) for 30 mins. at 
RT. 
xii) Washing in PBS as in step iv. 
xiii) Incubation in 25 //g DAB + 750 mg glucose dissolved in 50 ml 
PBS (O.IM, pH 7.1) in a coplin jar left overnight at room 
temperature in a dark place. 
xiv) Washing in distilled water (1 min. x 3 changes). 
xv) Immersion of slides in 1% acetic acid (1 min.) 
xvi) Counterstaining was done as usual. 
xvii) Finally sections were dehydrated and mounted in Canada bal-
sam and studied under the microscope. 
Controls 
i. Sections from postmortem anterior pituitary were used as posi-
tive controls. 
ii. Sections from lymph node were used as negative controls. 
iii. Omission of primary antibody and substitution with appropriate 
diluiior, of BSA. 
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RESULTS 
One hundred and seven formalin fixed paraffin embedded breast tissue 
sections were stained for localisation of PRL hormone receptor sites. Among 
these thirty five and twenty eight adjacent sections were also stained for FSH 
and LH binding sites respectively These could be classified as malignant, 
benign non proUferative breast disease, benign proliferative breast disease, 
lactating adenoma and Gynaecomastia. The percentage positive im-
munocytochemical staining of the three above mentioned peptide in each 
group are given in Table 3.2. Positive immunostaining reaction was 
predominantly localised in the cytoplasm of the epithelial cells present in 
various breast lesions and was heterogeneously distributed. Sometimes there 
was irregular staining of the cell periphery and some nuclei. Epithelilal cells 
of both duct and acini showed positive staining. In some, the staining was 
consistent in all ducts and lobules whereas in others there was a variation in 
intensity of staining reaction between ducts and their associated lobules. 
Table 3.2 
Positive staining of various breast lesions for PRL, FSH 
and LK binding sites 
Lesions 
Malignant 
Non-proliferative 
bsni^ Ti b'"*^ ^^ ^ ioci"ir) 
Proliferative benign 
breast disease 
Lactating adenoma 
Gynaecomastia 
PRL 
No. 
33/40 
32/50 
3/7 
2/2 
1^ 8 
% 
82.5 
64 
48 
100 
12.5 
FSH 
No. 
9/15 
7/14 
1/3 
0/1 
1/2 
% 
60 
50 
33 
0 
50 
LH 
No. 
4/10 
6/12 
1/3 
0/1 
' 1/2 
% 
40 
50 
33 1 
0 
50 
60 
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PRL binding 
Malignant (Carcinoma): Majority (82.5%) of the breast carcinoma 
sections (33/40) revealed positive staining for PRL binding sites (Fig. 3.2). 
In some carcinoma cases, majority of cells were positive v/hereas in others the 
positive staining cells were intermixed with negative cells thus showing 
hetergeneous reaction (Fig. 3.3). Ommission of primary antibody resulted in 
negative staining (Fig. 3.4a and 3.4b). 
Table 3.3 
Immunocytochemical reaction In different histological types of 
breast cancer 
Different Histological 
Types of Carcinoma 
Well differentiated 
(ductal carcinoma) 
Poorly differentiated 
Papillar adenocar-
cmoma 
Lobular carcinoma 
Carcinoma associated 
with Paget's diesease 
Metastasing into 
lymph node 
No. of 
Cases 
19 
2 
3 
6 
2 
8 
Immunocytochemical reaction 
Weak 
7 (36.8%) 
1 (50%) 
1 (33.3%) 
1 (16.6%) 
2 (100%) 
-
Mod. 
5 (26.3%) 
-
-
2 (33.3%) 
-
5 (62.5%) 
Strong 
6 (31.5%) 
' 
-
-
-
-
3 (37.5%) 
Neg. 
1 (0.5%) 
1 (50%) 
2 (66.6%) 
3 (50%) 
-
-
On further analysis of grade of malignancy in relation to im-
munocytochemical stairiing it was observed that well differentiated ductal 
tumiours showing stronger positive staining and had more cells reacting as 
r . T 
were stained (Table 3.3). Out of three cases of papillary'carcinoma one 
showed weak reaction with only few cells stained while other two cases were 
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Pig. 3 .2: Breast carcinoma - Section showing pos i t ive staning 
for PRL binding s i t e s . 
Fig . 3 .3 : Breast carcinoma -showing h e t e r o g e n i c i t y of 
immunocytochemical s ta in ing. 
Fig. 3.2 
Fig. 3.3 
Fig. 3.4a:Carcinoma breast - Positive for PRL bindilig sites. 
Fig. 3.4b:Above case 
omitted. 
- Negative staining when primary antibody is 
Fig. 3.4 a 
Fig. 3.4 b 
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completely negative. Similarly, lobular carcinoma and carcinoma associated 
with Paget's disease were weakly positive. Howevei; the metastasing tumours 
showed stronger reaction with more number of cells showing positive reaction 
whereas the lymphocytes were negative (Fig. .3.5). The normal epithelial cells 
within the tumour areas were generally negative. 
A relationship between age of the patient and intensity as well as number 
of cells showing positive staining for PRL binding sites was observed. Majority 
of the breast carcinoma slides showed positive reaction, with many cells 
reacting, in tumours removed from patients above 41 years of age i.e. in the 
peri menopausal and post menopausal patients, whereas tumours removed 
from patients in yoimger age, the intensity of staining reaction was either 
poor or absent (Table 3.4). 
Table 3.4 
Relationship of Immunocytochemlcal reaction in breast carcinoma 
with age of patients 
Lesions 
Carcinoma 
Age 
Group 
<30 
31-40 
41-50 
51-60 
>60 
Positive 
No. 
2/3 
6/9 
14/16 
5/6 
% 
66.66 
66.66 
87.5 
83.3 
6/6 100 
i 
Negative 
No. 
1/3 
3/9 
2/16 
1/6 
-
% 
33.33 
33.33 
12.5 
16.7 
• 1 
Benign Non-Proliferadve breast disease: This group included 
fibroadenoma, apocrine metaplasia, cysts and mild hyperplasia of usual type. 
Fibroadenoma (no. of cases 43) comprises the major group of non-prolifera-
tive lesions in this study Among the forty three cases of fibroadenoma two 
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Fig. 3.5: Metastatic carcinoma lymph node -Showing positive 
" staining for PRL binding sites. Note that the carcinoma 
cells are positive whereas the lymph node parenchyma is 
negative. 
h g" 3 5 i 
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were associated with apocrine metaplasia while two were associated with 
lactating breast. Leaving aside these four cases, twenty one cases (54%) of 
fibroadenoma out of 39 showed positive staining for PRL binding sites (Fig. 
3.6). The rest were negative (Fig. 3.7). The apocrine metaplasia associated 
with fibrodaenoma were more intensely stained whereas ductular lining 
epithelial cells of fibroadenoma were either negatively or weakly stained (Fig. 
3.8). The lactating breast associated with fibroadenoma were also positively 
stained. Three other cases of apocrine metaplasia associated with either 
epitheUosis, or pappillomatoid hyperplasia were also positive for PRL binding 
sites (Fig. 3.9a,b,c). EpitheHosis and papillomatoid hyperplasia were 
hetrogeneously stained. Other non-proliferative lesions showing duct ectasia, 
galactocele and benign cystic mastitis were also positive for PRL binding sites. 
Proliferated benign breast disease: This group included atypical lobular 
hyperplasia, atypical "ductal" hyperplasia, moderate and florid hyperplasia of 
the usual type (epitheliosis), papillomas, ductal involvement v^th cells of 
atypical lobular hyperplasia and sclerosing adenosis. Out of 7 cases only three 
showed positive staining for PRL, the staining was weak and heterogeneously 
distributed. Epitheliosis present in three cases, two showed heterogenous 
staining. Lobular hyperplasia were positively stained (Fig. 3.10). 
Lactating adenoma: Two cases of lactating adenoma gave intense in-
tracellular positive staining for PRL binding sites (Fig. 3.1 la.b). 
Gynaecomastia: All the cases of gynaecomastia included in the study 
except one were negatively stained for PRL binding sites. 
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Pig. 3.6: Fibroadenoma breast - Showing positive staining for PRL 
binding sites. 
Pig. 3.7: Fibroadenoma breast (another case) - Showing negative 
staining for PRL binding sites. 
Fig. 3.6 
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Fig. 3.7 
Fig. 3.8: Fibroadenoma associated with apocrine cyst. Note that 
the apocrine cells are positive for PRL binding sites 
whereas ductular lining epithelial cells of 
fibroadenoma are either negative or weakly positive. 
Fig. 3.8 
Fig. 3.9a:Apocrine cyst - showing intense positive reaction of the 
metaplastic epithelial cells. 
Fig. 3.9b:Higher magnification of the same case. 
Fig. 3.9c:Same case, negative staining when primary antibody is 
omitted. 
Fig. 3.9 a Fig. 3.9 b 
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Fig. 3.10:Lobular hyperplasia breast - Showing positive reaction 
for PRL binding sites. 
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Fig. 3.11(a): Lactating adenoma breast - H.E. staining 
Fig. 3.11(b): Positive reaction for PRL binding sites. 
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FSH and LH binding 
Staining intensity for FSH and LH binding sites was not as much as that 
for PRL binding sites. In most of the carcinoma cases LH staining was absent 
whereas FSH staining showed weak reaction (Table 3.2). In one case out of 
three of benign proliferative breast disease there was positive reaction for FSH 
and LH binding sites. Fibroadenoma cases showed mixed reaction for FSH 
and LH binding sites. There was no positive staining of FSH an LH binding 
sites in the benign cystic lesion of the breast. 
The control anterior pituitaiy sections were stained positive whereas 
sections of lymph node were not stained at all. These two tissues thus acted 
as positive and negative controls respectively in the present study. 
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DISCUSSION 
Immunocytochemistry has been extensively used as a tool to localise 
peptide hormone binding sites in the breast tissue. A fairly consistent presence 
of binding of peptide hormone in both benign and malignant breast tissue had 
been indicated. Sections of more than 5 years old paraffin blocks of formalin 
fixed breast tissue could be stained as we had employed a novel and a highly 
sensitive method of immunocytochemistry. EarHer the use of fresh frozen 
material was found Xo be essential for localising PRL binding sites in human 
breast tissue (de Souza et al, 1977; Dhadly and Walker, 1983). However; in 
the present study PRL, FSH and LH binding sites have been detected in paraffin 
embedded tissue and thus is contarary to the previous reports. Nevetheless, 
Pumell etal. (1982) and Marchetti et al. (1984) were able to demonstrate 
cytoplasmic PRL binding in paraffin wax embedded tissue but using an 
antiserum against bovine PRL. 
The binding sites for PRL were visualised by the antibodies against the 
hormone as the endogenous hormone is not destroyed after binding to its 
receptor. It remains bound to its receptors due to the very slow dissociation 
rate of the hormone from the receptor (Birkinshaw and Falconet; 1972). 
This study had demonstrated positive staining for PRL binding sites in 
82% of the malignant cases. However, only 58% positivity was obtained in 
the earlier study using paraffin section (Pumell et al, 1982). This variation 
could be attributed to the difference in the antisera, fixative and the technique 
used by them. The DHSS technique followed through out our study is more 
sensitive than PAP method. The dilution of primary antibody required for 
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Staining was also almost 100 times greater as compared to PAP techniques. 
The use of monoclonal IgM type of immunoglobulins as bridge antibody 
results in higher staining sensitivity (Jasani et al., 1983). Using the same 
technique as ours Kumar et al. (1987) had reported 73% positivity for PRL 
binding in carcinoma but the number of cases were too small (eight) for 
comments. 
The positive staining in the epithelial cells on the breast tissue sections 
was present intracellularly rather than at the periphery only. This was in 
consonance with the observation made by earlier workers (Nolin and 
Witorsch, 1976) and is in agreement with the concept of intemalisation of 
PRL receptor complex (reviewed in chapter IV). Pumell etal. (1982) had 
demonstrated cytoplasmic immunocytochemical staining for PRL binding sites 
but with different technique. Dhadly etal (1983) by treating the sections 
with purified human PRL prior to immunostaining steps obtained positive 
reaction at the periphery of both benign and malignant epithelial cells. 
Marchetti et al. (1984) in their study had observed that plasma membranes 
of these cells were never stained with PRL-antibody if the tissue were not 
pre-exposed to human PRL. However, we have in few cases obtained irregular 
staining at the periphery in addition to diffused cytoplasmic staining. The light 
microscopic studies did not permit us to identify the subcellular sites that 
contain the internalised PRL and the cytoplasm was seen to be stained giving 
positive reaction. 
In the present study, while stuaving tne immunocytochermcai reaction 
in the breast tissue, it was observed that the breast responds to the staining 
reaction heterogenously i.e. the immunostained cells were found generally 
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intermixed with variable number of unstained cancer cells. This observation 
is compatible with the previous immunocytochemical results, suggesting a 
heterogenous population of cells with respect to the PRL binding (Patterson 
etd. , 1982;Pumelletd., 1982;Dhadlyet a/., 1983). A high degree of tumour 
cell heterogenicity in breast carcinoma was suggested by the observatiion that 
significantly different proliferative rates were found for different epithelial 
cells cloned for different tumours (Schmidt- Ullrich, 1986). 
No previous immunohistochemical studies have however commented on 
staining reaction variation with menopaupsal status for cancer patients. In 
the present study, it was observed that majorit>' of the breast carcinoma sHdes 
of patients above the age of 41 years showed positive reaction. The finding 
of the PRL binding sites in greater proportion in peri and post-menopausal 
patients is of importance and is in consonance with the presence of estrogen 
receptor in breast cancer Older women were more likely to be estrogen 
receptor positive than younger women (Clark et ah, 1984; Bonneterre et al., 
1986). It was also observed by Kwa et al. (1981) that post-menopausal 
patients who subsequently developed breast cancer have elevated levels of 
PRL upto 5 years before the clinical diagnosis of the disease and this elevated 
PRL levels in post menopausal women may result in increase number of PRL 
receptor in the mammary tumour tissue that may cause the regrowth of 
epithelial tissue (Jensen HM, 1981). In addition estrogen, in the peri and post 
menopausal period, hypothetically is considered to be the key determinant of 
sub»c4ucixi iiik fvji I:<iLaSt canCti', iViay iz indirectly ^y stimulating ritL 
receptors in breast, thus promoting cellular susceptibility to neoplastic trans-
formation (Kelly ef a/., 1980). Willis era/. (1977) suggested that in addition 
Iinmunocylochemical localisation 
to the tamoxifen treatment given to postmenopausal breast cancer patients 
for lowering estrogenic effect, their PRL production should also be suppressed 
by the drug such as bromocriptine. This would decrease the endogenous PRL 
levels which in turn vv^U decrease proliferation of bresat tissue. 
It was also interesting io note in the present study that histopathological 
differentiation of breast tumours had got direct relationship with the presence 
of PRL binding sites. The well differentiated tumours showed staining reac-
tion, the stronger reaction shown by areas of ductular differentiation, whereas 
poorly differentiated carcinoma either had only few cells that were stained or 
were completely negative. Similar observation was also made by Dhadly and 
Walker (1983). The results are comparable with the presence of ER that are 
more often found in well differentiated tumours (McCarty ef a/., 1980). 
Metastasing tumours showed stronger reaction to PRL im-
munocytochemical staining in our study. This finding could be explained with 
respect to the assumption of Bami et al. (1987). PRL level rises more 
frequently after mastectomy in patient without node involvement, and if there 
was a stimulating role of PRL on breast cancer cells in humans, the high levels 
of PRL after mastectomy could stimulate the growth of micrometastases and 
this might represent a risk factor for relapse. Correlating the two, it could be 
stated that increased PRL level at any stage of women's life (including 
mastectomy) may have a stimulatory role on breast cancer cells. This could 
be manifested by increa:.ed binding titei. in metastdsiny iauioars ^>''^'i>>Ah 
et al. (1985) reported that patients wilh tumours having high PRL-R have 
significantly reduced survival rate and thus have poor prognosis. However, 
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Bonneterre et al. (1986) have presented opposite results. The serum PRL level 
estimated by various workers also supports the above view, the pre and post 
operative PRL level when related with prognosis, the highest one was found 
to have poor prognosis (Wang et al, 1986). The response to chemotherapy 
or endotherapy fails or becomes ineffective when serum PRL levels were 
increased in post menopausal women with advanced breast cancer (Dowsett 
et al, 1983). The hyperprolactenemia being associated with the progressive 
disease in majority of advanced breast cancer patients (Holtkamp etal., 
1984). Though it has been shown in experimental specimen that concentra-
tion of PRL-R in mammary tumours is independent of PRL concentration 
(DiCarlo et al, 1988) yet precautions must be taken prior to applying these 
data to hvunan. 
In the present study, the positive reaction for PRL binding sites was seen 
in good percentage of fibroadenoma cases (54%). This is contrary to earlier 
reports where less percentage or zero percentage of positivity was shown 
(Pumell etal, 1982; Kumar etal, 1987). The number of cases included in. 
these studies were less. However; our finding is in agreement with the study 
of EHermite Baleriaux and LHermite (1984) which have shown 50% positivity 
in fibroadenoma. In the present study cases of lactating breast and apocrine 
metaplasia exhibited positive staining. Apocrine metaplasia was reported to 
be associated with increased cancer risk (Page et al, 1978; Robert et al, 
1984) though later it was considered to be non- proliferative (Dupont and 
Page, 1985). The positive reaction in apocrine metaplasia was also shown by 
Kumar et al (1987) who considered the presence of PRL binding in these to 
be of significance in view of the hormone's known grQijst^^|Ti^^^^^5^ect 
^A51G \ ] 
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on the breast epithelium. Considering the observations of Robert et al. (1984) 
and Kumar et al. (1987) our finding could be useful for suggesting endocrine 
therapy to the patients with benign disease. 
A single case of duct ectasia showing positive reaction for PRL binding 
sites is in agreement with the finding of Shousha S et al. (1988) where higher 
levels of PRL were reported in these patients, indicating increased PRL to be 
the causative agent of duct ectasia. 
The weak and rather heterogenously distributed PRL staining in other 
types of both proliferative and non-proliferative benign breast lesions is 
difficult to rationalise. The classification of benign breast disease into non-
proliferative and proliferative breast disease (Dupont and Page, 1985) might 
be of clinical importance but when PRL binding sites was considered no 
definite conclusion could be made to distinguish between the two, may be 
because of small number of proliferative cases included in the study. 
Regarding other peptide hormones FSH and LH, this is only a prelimi-
nary study which have indicated that there are binding sites for these hormone 
in the tumour tissues of breast. The presence of high levels of PRL and rather 
low levels of FSH and LH in cystic fluid was reported (Bradlow et al., 1983). 
Our observation of positive staining for PRL and negative reaction for FSH 
and LH binding sites in cases of cystic disease is in agreement with this study. 
Not much work had been done relating to the role of these hormones in the 
etiology of breast cancer through analysis of LH-RH are used for the treatment 
of hormone dependent breast cancer 
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B. PRL BINDING SITES IN FNAC SMEARS 
MATERIAL AND METHODS 
The specimens were collected from sixty eight breast lumps in women 
by FNAC using 20 ml disposable syringe and 23/24 gauge needle. The 
aspirated material was smeared on multiple glass slides. These were fixed 
immediately in 95% alcohol. In all the cases, one or more smears were stained 
with routine haemotoxylin eosin for cytological diagnosis. The im-
munocytochemical staining was done on smears showing tumours, benign or 
malignant and benign diseases of the breast. Inflammatory lesions of the 
breast and the smears containing scanty material were excluded from the 
study. In sixteen cases only it was possible to study paraffin embedded 
sections of corresponding FNAC smears for PRL binding sites. Squash smears 
prepared from fresh pituitary gland obtained from postmortem room was 
included in each batch of staining as a positive control. For negative control, 
a l3miph node aspirate was used. Also in randomly selected smears primary 
antibody was substituted by BSA for second negative control. Positive reaction 
appeared as brown granules in the cytoplasm of the cells. 
The immunocytochemical teclmique utihzed here was the same as 
previously described for paraffin secfions except the dewaxing step which was 
encluded here. 
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RESULTS 
The immunocytochemical studies in FNAC for PRL binding sites were 
carried out in 68 cases (Table 3.5). There were forty seven cases of carcinoma 
and twenty one cases of benign breast disease. Benign breast disease were 
classified according to Dupont and Page (1985) into non-proliferative and 
proliferative benign breast lesions. 
Lesions 
1. 
2. 
3. 
. 
Malignant 
Non-proliferative 
Benign breast disease 
Fibroadenoma 
Blunt d*'ct Adenosis 
Apocrine cyst 
Proliferative benign 
breast lesions 
Sclerosing adenosis 
Lobular hyperplasia 
Atypical epithelial 
hyperplasia 
Total 
47 
5 
3 
5 
1 
6 
1 
Positive 
34 
3 
2 
4 
-
4 
-
Negative 
13 
2 
1 
1 
1 
2 
1 
Malignant (Carcinoma): This group included 47 cases of invasive ductal 
carcinoma. Of these thirty four (72.4%) cases of carcinoma gave intense 
positive reaction (Fig. 3.12) while thirteen cases (27.6%) were negative for 
PRL binding sites. However; six of the former cases showed variable reaction 
giving positive reaction in some neoplastic cells while others were negative. 
Non proliferative benign breast disease: There were five specimen of 
fibroadenoma. The cytodiagnosis of fibroadenoma was given when smears 
contained sheets or clumps of monomorphic small cells with scant amount of 
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Fig.3.12i: FNAC smear of breast carcinoma - Showing 
staining for PRL binding sites. 
positive 
Fig.3.12ii: FNAC smear of breast carcinoma (another case) 
Showing positive staining for PRL binding sites. 
Fig. 3.12 i 
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cytoplasm. On immunocytochemical staining, three of these showed positive 
reaction though it was lighter as compared to malignant ones, whereas the 
other two cases were completely negative. Three cases of blunt duct and five 
cases of apocrine change were studied. In three instances of blunt duct 
adenosis the smears were hypocellular They contained epithelial cells of 
variable types and occasional spindle shaped cells. Two of these cases were 
positive for PRL binding sites whereas one was negative. In five cases of 
apocrine cyst the smears were hypercellular. The cells were oval or polyhedral 
in shape having small nuclear cytoplasmic ratio, well demarcated cell borders 
and granular cj^oplasm. They were arranged either in sheets or were isolated. 
Four of these gave positive reaction while one was negative (Fig. 3.13). 
Proliferative benign breast disease : The proliferative benign breast lesion 
includes sclerosing adenosis (1 case), lobular hyperplasia (6 cases) and 
atypical epitheUal hyperplasia (1 case). The semars in a solitary case, cytologi-
cally diagnosed as sclerosing adenosis, contained cells clumps showing 
anisonucleosis and hyperchromasia. This was negative for PRL binding sites. 
The six smears of lobular hyperplasia contained epithelial cells of variable 
sizes with moderate to abundant cytoplasm. The cells were arranged in clumps 
presenting branching pattern. Four of these cases showed positive staining 
(Fig. 3.14) while two were negative. In a solitary case of atypical epithelial 
hyperplasia, a few atypical epithelial cells were present in the smears. This 
case was also negative for PRL binding sites. 
m sixteen mstances immunocytochemical staining reaction in FNAC 
smears could be compared with corresponding paraffin sections. There were 
nine cases of carcinoma, three of fibroadenoma and four were benign cystic 
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Fig. 3.13:FNAC smear of apocrine cyst - isolated apocrine cells 
showing positive immunocytochemical reaction. 
Fig. 3.14:FNAC smear of lobular hyperplasia 
reaction. 
- Showing positive 
Fig. 3.13 
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disease with Apocrine metaplasia. In all the sixteen specimens in which 
corresponding paraffin section was stained a positive aPRL staining was 
obtained. However; on reviewing the FNAC smear slides of the sixteen cases, 
in two specimens the PRL staining was reported negative. These two cases 
were of carcinoma. 
The optimal staining reaction was obtained at the dilution of 1:15,000 
of a PRL diluted in BSA. A positive reaction for PRL was seen in all instances 
with section of anterior pituitary but there was no e /^idence of PRL binding 
in lymph node smears. Also omission of a PRL and its substitution with BSA 
abolished specific staining. 
84 
Immunocytochemical localisation 
DISCUSSION 
The PRL binding sites in breast cancer cells have already been 
demonstrated using immunocytochemical techniques in various preparations 
such as in tissue culture (Patterson etal, 1982), frozen sections (Dhadly & 
Walker, 1983) and paraffin sections (Pumell et al, 1982; Kumar et ah, 1987). 
However, till date v^ e had not come across any study demonstrating PRL 
binding sites immunocytochemically in Fine Needle Aspiration Cytology 
(FNAC) though estrogen (Coombs etal, 1987) and progesterone receptors 
(Lozwski et al., 1990) in smears of breast have been studied and its usefulness 
had been stressed. The prognosis significance of PRL receptor in human breast 
cancer has already been described (Waseda etal., 1985; Bonneterre etal., 
1986). The breast carcinoma cells in FNAC smears in this study presented 
heterogeneity as was demonstrated earlier in paraffin sections (Pumell 
et al., 1982; Kumar et al., 1987). The staining reaction was observed intracel-
lular which is in agreement with the concept of internalization of the hormone 
receptor complex (Djiane et al., 1981). 
The PRL binding sites observed in four cases of apocrine cyst in the 
present study is in agreement with the results of paraffin sections. 
When the results of immunocytochemical staining reaction were com-
pared with that of FNAC smears correlation was observed in about 80% of 
cases. In Uvo instances where the FNAC smears were negative and the paraffin 
section shovv^ ed heterogeniety of staining, probably the specimens with the 
needle were obtained from the negaiive pan of the lurnuur. Tu oveicomt: iius 
fallacy multiple smears from different parts of the tumours and metastatic 
sites may be prepared and stained wirh same immunocj^ochemical technique. 
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In view of these findings demonstration of PRL binding sites may be 
proved a useful marker for determining high risk benign breast disease by 
immunoc>l:ochemical staining even in FNAC smears, which is a very simple 
cost effective, and can be utilized repetitively without causing any stress of 
operation to the patient. The procedure has been adopted as routine diagnos-
tic tool for breast lumps in many laboratories. 
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Si^tdiriQ Sites 
OBJECTIVES AND PLAN OF WORK 
The plasma membrane is the reception site for the peptide hormones, 
but the hormonal activity is elicited in the cells upon internalization of the 
hormone- receptor complex (Kahn era/., 1981). f'or manifestation of the 
hormone effect, amount of hormone in circulation and the responsiveness of 
the target tissue to the specific hormone are the two important factors. This 
in turn depends upon the receptor level of that hormone. Any deviation of the 
receptor level on either side v^ i^ll influence the occurrence of the disease. As 
discussed earlier the reproductive endocrine system which changes during the 
life time of v^omen may contribute considerably to the aetiology and 
pathogenesis of breast disease. The role of PRL in the pathogenesis of human 
breast cancer is still not fully elucidated. There are some studies w h^ich have 
reported the presence of PRL-R in human breast tumours. They all had used 
crude membrane preparation for determining the specific binding of PRL-R. 
No study has used the purifed plasma membrane for this purpose. 
The aim of this study was therefore to biochemically determine the PRL 
binding sites in the purified plasma membrane and crude membrane of the 
breast tissue. 
We have followed the method of sucrose density gradient centrifugation 
(Neville DM Jr, 1960) for the preparation of purified plasma membrane from 
normal, benign and malignant breast tissue. The separation of cellular 
organelles depended upon the isopymic densities. Crude membranes were 
prepared according to the method of Peyrat et al. (1982). Binding studies were 
done in both the types of membranes for PRL receptors. 
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INTRODUCTION 
Breast, as mentioned earlier in Chapter II, may be the target organ for 
various peptide hormones and may undergo changes in response to secretion 
of gonadotropic hormones. In human mammary tumours the existence of 
PRL-R has been reported (L-Hermite Baleriaux et al, 1987). There are 
evidences to suggest that looking for the binding site for PRL in normal and 
pathological state could probably establish some therapeutic importance. 
The binding activity of PRL to a specific cellular receptor has been 
identified in several organs of various species though the effect of PRL in all 
these organs is not completely known. 
PRL receptoi; the binding unit has been identified and purified by 
different biochemical techniques mainly from the rabbit mammary gland 
(Necessary et al, 1984; Djiane et al, 1985; Sakai et al, 1986) and some of 
their physico-chemical properties have been determined (Haeuptle et al, 
1983; ICatohef al, 1984; Djiane et al, 1985). PRL receptors are hydrophobic 
glycoproteins which possess very high affinity for PRL and related hormones 
possessing similar biological activity, for example GH and placental lactogenic 
homiones. Digestion with proteases and phospholipase C destroys the activity 
of the receptors (Shiu and Friesen, 1974). Like the other membrane proteins, 
it has its hydrophobic portion embedded in the lipid layer of the plasma 
membrane while its hydrophilic portion, the carbohydrate moiety, protrudes 
outwards. 
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The association and dissociaton constants of I labelled PRL are time 
and temperature dependent and the binding is influenced strongly by pH 
(optimum at 7.5-8.5). The ionic condition that is required is of calcium and 
magnesium ions and it remains unaffected by the presence of the wide range 
of low molecular weight compounds tested like steroids and nucleotides. 
Binding of the hormone to the receptor does not result in the destruction of 
biological activity of the hormone and a large portion of the hormone remains 
bound to the receptor inspite of mechanical stress due to homonization during 
membrane preparation. This is due to the slow rate of dissociation of PRL 
from its receptor (Birkinshaw and Falconer, 1972) or due to the irreversible 
nature of PRL binding to its receptor (Van der Gugten et ah, 1980). 
PRL-R are ver>' short-lived molecules in the mammary gland. When the 
mammary gland expiants are cultured in the presence of cycloheximide, 50% 
of PRL-R disappears from the membranes in less than 3 hrs, but the time 
increases to 24-48 hrs in the absence of the inhibitor When the transcriptional 
activity is blocked by actinomycin D, the level of PRL is only slightly modified 
though the milk protein synthesis is completely prevented (Shiu and Friesen, 
1980). It has been suggested that the short life of PRL- R is affected probably 
at translational or degradative steps. Degradation of the receptor occurs in 
the lysosomes as inactivation of these organelles by amines, such as chloro-
quines, ammonium chloride, results in a rapid increase in the PRL-R level. 
to respond to changes in ligand concentration by regulating their number or 
affinity of their surface receptors. The regulation of PPLL-R concentration by 
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various tissues appears to be quite complex (Posner et ah, 1975,1976). Other 
hormones also modify the number of PRL-R depending on the target organ 
studies (Yen et al, 1974; Kelly et al, 1977,1978). /n vivo, both 'up regulation' 
(Posner etah, 1975; Djiane etal, 1977) and 'down regulation' (Djiane 
et al, 1979) occur of these PRL-R. In vitro, PRL-R shows 'down regulation' 
in explant cultures having a relatively rapid turnover rate (Djiane et al., 1979, 
1982). The down regulation has been shown to be a multistep process starting 
by an internalization of the hormone receptor complex and resulting in its 
breakdown within the lysosomes. 
The mechanism involved in hormonal transduction remains unknown, 
however, the possible step that follows after the hormone binding to its 
receptor has been stated as their internalization and association partly with 
golgi elements and partly with lysosomes (Kelly et al, 1980). The biological 
activity could be induced by the hormone-receptor complex either acting 
directly at the level of the nucleus or the lysosomal degradation of PRL and/or 
the alteration of PRL owing to its association with golgi could also result in 
products that might act on nucleus. 
The concept that peptide-hormone receptors are preferentially con-
centrated on plasma lemma seems less plausible now by a number of studies 
that have demonstrated the binding of labelled hormones to the intracellular 
membranes (Djiane et al, 1981; Posner et al, 1982). Djiane et al (1981) by 
pcrfcrrrung disconrinucuc sucrose gradient ultracentrifugaiicn and purifying 
the plasma memberane and golgi component showed that despite the initial 
step of binding of PRL to the plasma memberanes, most of the PRL-R appeared 
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to be located within the cell rather than at the level of plasma membrane. 
PUiified golgi fraction of rat liver cells v^ere found to be richer in PRL-R and 
have higher affinity for PRL than plasma membrane fractions (Kelly et al., 
1983). These studies also lend support to the view that the down regulation 
of PRL receptors occurs initially at the cell periphery reinforcing the theory 
of the internalization of the hormone-receptor complexes and their sub-
sequent degradation. In the lactating mammary cell about 70% of the PRL-R 
are intracellular receptor and thus these receptors are not recognised by the 
hormone in their first step of binding (Djiane etai, 1985). Howevei; in 
another study smooth membrane preparations of pregnant and lactating ewes 
were found to be richer in PRL-R than the microsomal preparations (Emane 
etai, 1986). 
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MATERIALS AND METHODS 
Materials 
Patients admitted to the 'indoor wards' of the King George's Medical 
College, who underwent breast biopsies or mastectomy were included. Biopsy 
piece thus obtained from operation theatre was divided into two pieces. One 
was sent for histopathological study while the other adjacent one was 
immediatley frozen at -20°C till further biochemical processing. 
Methods 
Isolation of plasma membrane 
Plasma membrane fractions were obtained from human mammary 
tissue by a method of Neville DM Jr. (I960) as modified by Emmelot et al. 
(1964). All the operations during membrane preparation were carried out in 
a cold room at 4°C. Tissues from -20°C were thawed and then washed with 
ice-cold 0.25M STM buffer (pH 7.4) consisting of sucrose (0.25 M), Tris HCl 
(4 mM), and MgCl2 (ImM). It was cut into small pieces removing all the 
visible fat. These were again washed and weighed. It was then minced finally 
with scissors on glass plate kept on ice. Minced tissue was suspended in 
homogenization medium (1 gm/4 ml of 0.25 STM buffer) and homogenized 
in an all glass homogenizer (50 ml capacity) of the Potter-Elvehjein type wdth 
Teflon pestle normally using five up and down strokes at medium speed. The 
homogenate was filtered through prewetted cheese cloth (four layers). While 
homogenising, protease inhibitor in sufficient amount was added drop wise. 
The filtered homogenaxe was centrifuged. at 280 g for 5 nun. at 2^C in an 
RC5C centrifuge. The intact cells, debris and nuclei settle down. The super-
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natant was carefully decanted off and then centrifuged at 1500 g for 10 mins 
at 2°C in the same centrifiuge. The resultant supernatant was discarded and 
the pellets were pooled, suspended in homogenizing medium and washed 
Uvice or thrice. Plasma membranes were isolated from the fraction by sucrose 
density gradient. Briefly, the pellet was suspended in a mixture of 0.25 M 
STM (density 1.02, volume 1.5 ml) and 2M STM (density 1.24, volume 5.5 
ml). This mixture overlaid by 0.25 M STM was ultracentrifuged at 25000rpm 
at 2°C in an SW28 rotor of Sorvall ultracentrifuge. Pelicle of plasma 
membrane was formed at the interface (densityl.18 g/cm ). This was care-
fully aspirated by a pasteur pippette and resuspended in 0.25 M STM buffer. 
This preparation was washed with normal saline and then stored in ice for 
further biochemical estimations. 
Crude Membrane Preparation 
Crude membranes were prepared following the method of Peyrat 
et al. (1982). Briefly, tissues were treated in the same fashion as above except 
the homogenization step. In this case, the buffer (pH 7.8) contained Tris 
(0.025 M), EDTA (3 mM), dithiothreitol (1 mM) and azide (0.01%). 
Homogenate was centrifuged at 800g in RCSC for 10 min. at 2°C. The 
supernatant thus obtained was ultracentrifuged at 1,05,000 g for 60 min. at 
2°C in a swing-out rotor of Beckmen Ultracentrifuge. The pellet was 
suspended in 25 niM Tris containing 10 mM MgCb (pH 7.6). 
Protein was measured according to Lowry et al (1951) with Bovine 
serum albumin as the standard. 
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Enzyme Assay 
The marker enzymes were assayed qualitatively so as to ascertain the 
purity of the plasma membrane thus prepared. 5'- Nucleotidase (EC 3.1, 3.5) 
assayed according to the method of Serrano et al. (1977). The assay mixture 
consisted of Tris- HCI (100 mM) buffer (7.4), 10 mM MgCl2, 5 fiM 5'AMP 
sodium salt and suitably diluted enzyme in a final volume of 0.5 ml (100-200 
yUg of protein). The reaction mixture w^ as incubated for 30 min. at 37°C. It 
was terminated by adding 1 ml of prechilled 10% TCA and the liberated 
phosphate in the supernatant was estimated and OD was read at 620 nm. 
Alkaline phosphatase (EC 3.1 3.1) assayed according to the method 
described by Bessey et al. (1946) with slight modification. The reaction 
mixture in a total volume of 2 ml consisted of 200 mmoles bicarbonate buffer 
(pH 9.5) + 3 umoles p-nitrophenyl phosphate as substrate and suitably 
diluted enzyme. After incubation at 37°C for 30 min., the reaction was stopped 
by adding 2 mi of 0.1 N NaOH. The appearance of p-nitrophenol was read at 
405 nm. 
To assay Glucose 6-phosphate, the reaction consisted of the same 
reagents as was taken for 5' nucleotidase, except the substrate which was 0.1 
M glucose-6-phosphate here. All the other steps were the same. Phosphate 
Uberated was estimated and OD was read at 620 nm. 
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Electron Microscopy 
Membranes were pellted by centrifugation and were fixed in buffered 
3% glutaraldehyde (pH 7.2-7A) for 1 to 2 hrs. The fixed pellets were washed 
several times in cacodylaie buffei; post fixed in buffered (pH 7.2) 1% osmium 
tetraoxide solution for 1 hr at 4°C. It was again washed to remove excess of 
Os04 with buffer and dehydrated by several changes of graded concentrations 
of acetone, treated with various combinations of acetone and Durcapan ACM 
mixture and then embedded in Durcapan ACM mixture. The ultrathin sections 
were stained with uranyl acetate and lead citrate and examined under 
transmission electron microscope (Philips 301). 
Alternatively, the plasma membrane preparations were diluted 10 times 
and a drop of suspension was placed on formvar coated grid. The grids were 
dried and then floated on a drop of 1% aq. phosphotungstic acid, again dried, 
and observed under the electron microscope. 
Electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis was per-
formed according to Laemali (1970). The concentration of resolving acryl 
amide gel was 10% and that of stacking gel was 5%. Sample'was solubiHzed 
in 5x sample buffer consisting of 0.08 M Tris (pH 6.8), SDS (2% w/v) glycerol 
(10% v/v) and beta-mercaptoethanol (5%), and heated for 2-3 min. in a 
boiling water bath prior to loading on gels. Running buffer containing 0.025 
M Iris, 0.112 M glycine and 0.1% SDS (pH 8.5J was used, 'ihe gels were 
stained with Coomassie Brilliant Blue R- 250. 
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Immunoblotting 
Malignant plasma membranes preparations (purified, 2 samples) were 
electrophoretically transferred from polyacrylamide SDS gels to nitrocellulose 
paper as described by Towbin et al. (1979). Briefly, membranes proteins were 
electrophoresed in the first dimension by the method of Laemali (1970). The 
proteins were then transferred to nitrocellulose paper. The electrode buffer 
used contain 25mM Tris, 192 mM glycine, 20% (v/v) methanol (ph 8.3). 
Staining of blotted proteins was done by amido black (0.1 % in 45% methanol, 
10% acetic acid) and then destained with 90% methanol and 2% acetic acid. 
The adjacent strip of nitrocellulose sheet having transferred proteins was 
treated by DNP labelled immunocytochemical technique previously described 
in chapter III except the inhibition of endogenous peroxidase step. The 
concentration of primary antibody (aPRL) was 100 times higher then that 
used for paraffin sections. After staining the paper with DAB it was dried and 
approximate Mol wt. of the bands were measured with reference to monkey 
erythrocyte membrane. 
Binding Studies 
Membranes prepared as described previously were frozen immediately 
at -20°C till the binding assay was carried out. No membranes were kept 
frozen for more than 2-3 days. Besides the membranes of different lesions of 
human breast, crude membranes of mammary glands of rat 5 days after 
partiution and livers of rats were also prepared so as to check the proper 
working of the reagents. Hormone used for the binding assay, i.e. h-PRL was 
purchased from Bioproducts-Iodination grade lot No. i017 Batch 016 + 017. 
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lodinatfon of PRL 
PRL hormone was labelled with I following the method of Green-
wood et al. (1963), using chloramine T as the oxidising reagent. Four/^g of 
PRL hormone dissolved in 40 fi\ of 0.05 M phosphate buffer (pH 7.4) was 
taken in a vial and 1.5 mCi of Na^^ I^ was added,5/ig/I0 ul of chloramine T 
solution was then added and the mixture was carefully vortexed. After 3 
minutes, the reaction was stopped by adding excess of bovine serum albumin 
in 0.05M phosphate buffer pH 7.4. Before transferring the mixture to the 
column for purification of labelled hormone, 10 ul of mixture was taken out 
in duplicate to determine the specific activity. 
Purification of the labelled hormone was done by column chromatog-
raphy. For this purpose, a column (0.5 x 50 cm) of sephadex G-75 was used. 
Prior to the use, 2% BSA in 0.5 ml volume of phosphate buffer (0.05 M, pH 
7.4) was allowed to pass out of the column so as to check the uniformity of 
the column. It was then thoroughly washed with the same buffer containing 
0.1% BSA. After loading the iodination mixture on the column the coluumn 
was eluted and 1 ml fractions collected. The radioactivity was measured by 
^^ r^ counts. 
Freeing of Receptors from the bound endogenous PRL 
As PRL does not dissociate from its receptors during the process of 
membrane preparation, a certain portion of the PRL receptors may be oc-
cupied by the endogenous circulating PRL. Thus these receptors could not be 
determined by the assay till the bound PRL is removed. For this, high 
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concentration of MgCL2 was used (Kelly et ai, 1979). Briefly, to one volume 
of membrane preparation six volumes of 3M MgCb was added. The mixture 
v^as vortexed and left for 3 min. at 4°C. The suspension was diluted with 4 
times the volume of ice cold 25 mM Tris buffer containing lOmM MgCh- The 
whole suspension was centrifuged and at 25,000 g for 30 min. at 2 C. The 
resulting pellet was resuspended in the above buffer and proceeded for the 
binding assay. About 50-60% of the total protein present in the preparation 
was lost during the above procedure. 
Binding Assay 
Method of CHermite-Baleriaux etal. (1987) was followed for the 
binding studies. Briefly, the membrane preparations were thawed and protein 
was estimated (Lowery etal, 1951). Preparations containing 400 ug of 
protein were taken in four tubes. Two of them were subjected to MgCh 
treatment, while the other two were left as such. These membranes with 
approximately 100,000 cpm of I-PRl were then incubated in a final volume 
of 0.5 ml buffer (Tris 25 mM, MgC]2 lOmM, BSA 0.1%) in the presence or the 
absence of excess of unlabelled hormone (l/<g). The incubation was per-
formed at 37°C for 1 hr and then left at room temperature overnight. Next 
day, the reaction was stopped by adding 3 ml of the cold buffer. The tubes 
were then centrifuged at 1500 g for 30 min. at 4°C to separate the bound 
I-PRL from the unbound labelled hormone. After decantation and drying 
the side of the tubes properly, the pellets were counted in a gamma counter. 
Specific binding (SpB) was calculated as the difference between the cpm 
bound in the absence and the presence of the excess unlabelled hormone and 
expressed as the percentage of the total radioactivity added in the tube. 
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RESULTS 
Pure plasma membranes were prepared from twenty five different types 
of breast tissues obtained fresh from surgery operation theatres. We were 
successful in obtaining the plasma membranes from nineteen cases only. The 
failure in getting the membranes from the six tissues was either due to excess 
fat along with the normal breast parenchyma which interfered with the 
membrane preparation process or due to uncalled technical problems. The 
plasma membrane thus obtained was tested for the marker enzymes, and was 
found to be enriched with two positive markers 5'nucleotidase and alkaline 
phosphatase but the enzyme Glucose 6- phosphatase was absent. Yield of the 
plasma membrane from the malignant tissue ranged from 0.6 to 0.9 mg 
protein/g wet tissue while from the benign tissue it was O.Sil mg protein/g 
wet tissue. The yield for normal tissue was the lowest, 0.1 mg protein/g wet 
tissue. Electron microscopic examination of the fractions showed that they 
were composed largely of heterogenous vesicles (Fig. 4.1). For further char-
acteristics, electrophoreric profiles of the polypeptides were examined. The 
pattern obtained by sodium dodecyl sulfate polyacryl amide gel 
electrophoresis of the three types of the membrane fractions are shown (Fig. 
4.2a) in comparison with that of the monkey erythrocyte membrane. 
The immunoperoxidase electrophosis (immunoblotting) of pure plasma 
membrane of two malignant revealed a sharp band at approximately 25kDa 
The iodination mixture that was loaded on the column was collected in 
1 ml fraction. The radioactivity in these fractions was measured. Three peaks 
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Fig. 4.1 Pure plasma membrane fraction of malignant breast 
tissue: Electron microphotograph x 9900 
r> 
Fig. 4.1 
Fig.4.2a SDS-Polyacrylamide gel electrophoresis of pure plasma 
membrane proteins of human breast tissue (including 
monkey erythrocyte as reference). 
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Fig.4.2c Nitrocellulose imitiunoblotting of the above two malignant 
plasma membrane preparation. Immunodetection of PRL with 
DHSS procedure using anti PRL and subsequent protein 
staining with DAB. Plasma membrane proteins (Case IV and 
Case V) were separated on 10% SDS-PAGE gel and 
electrotransferred onto nitrocellulose paper. 
b. Lane vi - Amido black staining 
Lane vii - Amido black staining 
c. Lane viii - Immunoblotting 
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of radioactivity were eluted. The first peak represented the damaged PRL 
aggregate, while the second peak was of the monomeric labelled PRL. The 
third peak was of free iodine. The second peak was pooled and used for the 
binding assay. The specific activity was calculated as 35 uci/iJg. 
The specific binding of crude membranes prepared from 2 out of 5 
malignant tissues was above 0.8%. Thus these membranes were considered 
positive for PRL-R. The specific binding was increased by treating the 
membranes with MgCb. No binding was observed with the pure plasma 
membrane of the above two cases. Specific bindings of lactatingrat mammary 
tissue and rat livers were higher than 0.8%. 
No binding was seen in both the cases of fibroadenoma included in the 
study. 
These results indicate that there are specific binding sites of PRL in the 
malignant breast tissues. 
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DISCUSSION 
According to the technique which we have followed for preparing pure 
plasma membranes, the cells get ruptured and nuclei and nuclear membranes 
get largely solubilized. The cell membranes, the largest fragments left in the 
homogenates, are pelleted by a low speed centrifugation. Microchondria and 
microsomal fragments that are more dense and smaller in size are separated 
from these membranes by the sucrose density gradient centrifugation. The 
only problem faced during the procedure was that of the plasma membrane 
yield, which was quite poor. This problem was serious in case of normal breast 
tissue which was full of fatty material. Also due to the awareness of the 
disease, breast cancer is usually eliminated before its enlargement, and only 
a small piece is available for the studies. The small fraction of plasma 
membrane obtained was not sufficient for the binding studies. Yield of the 
plasma membrane was highest for the malignant and lowest for the normal 
tissue, possibly because the normal mammary tissue is rich in connective 
tissue and fat whereas in the malignancy, epithehal cells increase. Positive 
reaction for the marker enzymes in the test as compared to the control 
confirmed presence of plasma membrane in the preparation without much 
contamination by the organelle membranes. Electron micrographs show that 
purified plasma membrane preparations were mainly composed of plasma 
membrane vesicles. 
Trie Stilli llLiii::'!! ?r.L used '".: ;::iii:'ji;'jbloi.iill^ vVCfe able io '^ '"ii ' •."""O 
bands in malignant pure plasma membrane preparations. The predominant 
one (25 kDa) may corresponds to PRL found in malignant tumours. The other 
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diffused band at 29 kDa may be the immuno-reactive variant of PRL. This 
observation may indicate that some of the plasma membrane receptors of PRL 
are also occupied by endogenous PRL. This finding agrees with the im-
munocytochemical results where in some cases membrane of epithelial cells 
in malignant tissue were also stained. 
Results of PRL binding study indicate that breast tumours contain low 
but measurable levels of PRL binding sites in crude membrane preparations. 
Such low binding was observed in earlier studies also (Di Carlo et al, 1979, 
Turcot Lemay and Kelly 1982; Murphy et al, 1984). Howevei; these studies 
differed from the present study in the percentage of PRL-R positive tumours. 
Di Carlo et al. (1979) reported 49% positivity for PRL-R in mahgnant tumours 
and 30% in benign breast tumours (Di Carlo et al, 1983) while it was only 
13% in other studies (Turcot- Lemay et al, 1982). Murphy et al (1984) 
reported the highest incidence (65%) The results are rather controversial due 
to the techniques used by these workers. Mainly the technique of membrane 
preparation, the label used for displacement studies and the interpretation of 
the results contributes to these differences. 
The binding was increased upon treating the tissue with high concentra-
tion of MgCb in the present study This data is in agreement with the findings 
of Peyrat et al. (1982), v/here 49% of the tumours were found positive by 
assaying the free PRL receptors (sp B=1.95±0.15%). Howevei; after the 
MgCi2 ireauirtfiL, 71% vi iht; i-i-ouxi weic PRL-R positive (s^ ^ B -
3.17±0.27%). It was suggested that some PRL-R were occupied by the 
endogenous PRL especially when elevated by stress and or anesthetic drugs 
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and due to the irreversible nature of the PRL binding to its receptors (Vander 
Gugten et al.^ such occupied will remain undetected unless an in vitro 
A 
dissociation procedure is applied. These receptors do not become completely 
free even under stress during homogenizing (Kelly et al, 1976). The MgCb 
treatment induces the dissociation of endogenous PRL from the receptors. The 
detection and measurement of these PRL receptors in the cancerous tissue is 
necessary for predicting responsiveness to hormonal therapy. The endogenous 
bound PRL to its receptors was detected immuno-cytochemically as seen in 
previous chapter 
However; the problem is encountered in ascertaining the stage at which 
this 'in vitro' desaturation procedure is to be followed, as it could be done at 
three different stages, viz. 
i) during homogenization procedure (Calvo et al, 1981). 
ii) before the binding assay (Peyrat et al, 1982). 
iii) after incubation with the labelled hormone had been performed 
(Vander Gugten, 1980). 
The extent of binding will be different with all the three cases mentioned 
above. This treatment also resulted in a loss of about 60-61% of the 
measurable protein content and no study had taken this fact into account. 
It is im.portant to consider the reasons for the presence of this en-
dogenous PRL in the malignant tissue observed in the present study by 
biochemical as well as immunocytochemical methods. It could not be due to 
surgical stress per se, as suggested by Peyrat et al. (1982) since no PRL 
increase v^as shown in patients treated with the same type of anesthesia who 
underwent surgety for reasons other ihan breast cancer by other studies. It 
106 
Biochemical estimation 
could be possible that breast cancer were associated with the secretion of an 
unlmown factor acting at the hypothalamic- pituitary level to enhance the 
PRL secretion in the circulation and a portion of the PRL binding sites could 
be occupied. It could also be possible that the tumor itself secretes PRL and 
this results in occupancy of some sites in tumours. These data would thus 
indicate that PRL might be significant in the supporting the growth of breast 
cancer in vivo, and/or the hyperprolactinemia might be only a consequence 
of the progression of the disease as increased PRL level 5 years prior to the 
clinical appearance of the disease was reported (Kwa et al., 1981). 
We had prepared both pure and crude membranes from the breast tissue 
and proceeded for the binding assay. The maHgnant tissue whose crude 
membranes were positive for PRL binding sites, their pure plasma membranes 
preparations were negative. Though the number of specimen studied were 
less, this finding is in agreement with the reports of the previous workers 
(Djiane et al, 1981; Posner et al, 1982; Kelly et al, 1983). This was further 
supported by our immunocytochemical studies in which staining reaction was 
intracellular as discussed earlier. The negative binding in pure plasma 
membranes of these is however questionable. In addition, we could not get 
any PRL binding with the pure plasma membranes of lactating mammary 
tissue, like the earlier study wliich reported that in the lactating mammary 
cell, about 70% of the PRL receptors are intracellular receptors (Djiane 
et al, 1985). However, we could nor verify the presence of PRL receptors 
intracellulariy by the binding assay in the crude membrane preparation due 
to the scarcity of the lactating breast tissue. The present study differs from 
the studies of Emane et al (1986) in ihis respect. 
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PRL-R present in cancerous tissue may have a stimulating effect on the 
tumour. Drugs for removing PRL from the circulation could have some 
beneficial effects. Hormonal therapy with drugs for reducing PRL deserve a 
careful controlled clinical trial as the results may vary. Usually, the status of 
PRL in the body is determined by performing radioimmunoassay. Im-
munoreactive PRL may not be identical to PRL that is biologically active. 
Subramanian and Gala (1986) reported three forms of circulating PRL. The 
two larger forms that were found in the subjects with breast cancer (Sub-
ramanian and Gala, 1986) usually remain undetected by the routine radioim-
munoassay. On the other hand, small fragments of PRL molecule, detected in 
women with familial history of breast cancer by a specific assay, were also 
considered to have some role in induction of breast cancel; especially in 
sensitive subjects during some period in their life (Love RR and Rose DPO, 
1985). 
Although this study has succeded in determining the PRL binding sites 
both immunocytochemically and biochemically in benign and malignant 
breast lesions, it could havebeen more informative if the same tissue were 
used in both the methods. The logistics of experimental conditions in the 
present study precluded such investigations. 
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Following conclusions were drawn from this study:-
1. Formalin fixed, paraffin embedded upto five years old or more 
breast block tissue sections could be used for demonstrating specific 
peptide hormone binding sites. 
2. The immunostaining was mainly intracellular and was 
heterogeneously distributed. 
3. The breast carcinoma tissue slices showed more consistent im-
munostain as compared to benign breast disease. Since PRL binding 
sites were more commonly seen in the carcinoma breast tissue, one 
cannot exclude the possibility of the role of PRL in mammary 
tumourigenesis. 
4. Apocrine changes in epithelial lining had specific PRL binding sites. 
This finding may also suggest a role of PRL in the etiology of breast 
cancer through the induction of apocrine change as the later is 
associated with an increased risk of cancer. 
5. PRL binding sites were present in greater proportion in peri and 
post menopausal breast cancer patients. 
6. PRL binding sites could also be determined in cytology smears 
which results in cells sufficieni for immunostaning. 
7. The results of immunocyrochemistry on FNAC smears are com-
parable with that of hisiologic sections. Thus FNAC being economi-
cal, quick and non traumatic procedure could be more readily used 
tor the hormonaJ study. 
8. Thus study has demonstrated low amount of PRL-R in crude malig-
nant breast tissue membrane preparations. 
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Human breast is generally considered to be a passive organ being a 
target tissue for both steroids and peptide hormone. However, in an article it 
v^as suggested that breast may also be a primary endocrine organ. Prolactin 
is known to affect the milk secretion but whether other peptide hormones 
have any direct action on breast is unknown. However leutinizing hormone 
releasing hormone analogue has been shown to be effective in treatment of 
advanced breast cancer. 
Steroid honnones with estrogenic properties are largely accepted as 
potential promoters in the progression of human breast cancer and act 
through hormone-specific receptor protein. 
It has been recognised for a number of years that pituitary prolactin has 
also a powerful stimulating effect on the breast and on some types of breast 
cancer in experimental animals. 
If prolactin promotes hum.an breast cancer; then it would be expected 
that both the concentration of this hormone in the blood as well as the 
prolactin receptor concentration would influence prognosis in patients. 
Studies on prolactin levels in patients are contoversial, may be because of 
number of factors v/hich influence its secretion. 
Several mammary carcinoma cell lines were found ro have prolactin 
binding sites and prolactin was found to facilitate their growth. Specific 
binding of human prolactin of greater than 1% was seen in good percentage 
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human breast tumours. Therefore in view of all these observations it vi^ ould 
be interesting to see if there are any functional correlation and changes in the 
pathological state (benign breast disease and breast cancer) of binding v/ith 
the antibodies. Such a finding will open gates for a large number of experimen-
tation and treatment for breast disease. 
Keeping this in view the present study was undertaken to see if there 
are any specific binding sites for the peptide hormones in normal and 
pathological breast tissue. This was ascertained immunocytochemically. An 
attempt was also made specially in case of prolactin to biochemically quan-
titate these receptors in crude as well as in pure plasma membrane prepara-
tions. 
The first part of this study was immunocytochemical localisation of 
peptide hormone (PRL, FSH,LH) binding sites in benign and malignant human 
tissue. This was accomplished by using a highly sensitive immunocytochemi-
cal methodjthe dinitrophenyl hapten sandwich staining procedure and 
polyclonal antisera against peptide hormones. Both prospective and 
reterospective sections of formalin fixed paraffin embedded tissue of breast 
disease patients were immunostained. In this part of study an initial attempt 
was also made to immunostained fine needle aspirates of breast disease 
patient for prolactin binding sites. 
One hundred and seven formalin fixed paraffin embedded breast tissue 
sections were immunostained for localisation of prolactin binding sites in 
benign and malignant breast lesion ,^ /jnong these thirty five and twenty eight 
sections were also stained for FSH and LH binding sites respectively An 
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appropriate control slides were included in each batch of staining. Eighty two 
percent of breast carcinomas gave an intracellular positive reaction in tissue 
section for prolactin binding sites whereas, it was seventy two percent in fine 
needle aspiration. The intracellular localisation of prolactin could be the 
result of hormone intemalisation. In both the cases heterogeneity of binding 
was shown. In some cases iregular staining of the cell periphery was also 
observed. 
A definite relationship between age of the patients and intensity and 
occurenence of positive staining for prolactin was observed. Majority of the 
breast carcinoma slides showed positive reaction in tumours removed from 
patients during the peri and post menopausal periods. Whereas patients before 
40 years of age showed poor or irregular staining. Also poorly differentiated 
tumours gave less intense staining though metastasing tumours showed 
stronger reactions. 
Amongst the benign lesions immunostained, majority were 
fibroadenoma oi which 54% of cases showed positive staining for prolactin. 
The cells showing apocrine metaplasia associated with fibroadenoma were 
more intensely stained as compared to the ductular lining epithelial cells of 
fibroadenoma. Lobular h)q)erplasia, lactating adenoma and galactocele were 
also positively stained whereas epitheliosis and papillomalbid hyperplasia 
were heterogeneously stained. 
Staining for FSH and LH binding sites in breast tissue sections was only 
a preliminaty study. Though weak staining was obtained in most cases of 
carcinomen slides studied, no conclusion could be made for this binding. 
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The results of immunostaining on FNAC smears were comparable with 
that of histologic sections. Sufficient cells could be obtained by this method 
that can be immunostained for determining binding sites for prolactin. Fine 
needle aspiration cytology being economical, quick and non-traumatic proce-
dure could be more readily used for the hormonal study. 
In the second part of this study an attempt was made to biochemically 
quantitate prolactin receptors. For this both purified and crude plasma 
membranes of benign and malignant tissues were prepared. 
Pure plasma membrane were prepared by Sucrose density gradient 
method. The purity of the plasma membrane was checked by enzyme assay, 
electron microscope and electrophoresis. Western blotting of two pure plasma 
membrane preparations of malignant tissue were done and immunostained 
with DNP localisation imimunochemical method. Both pure plasma 
membrane preparations and crude membranes were used for binding assays. 
Radioactive labelling of prolactin with radioactive iodine was done using 
Chloramine T as oxidising agent and the radioactive hormone was purified by 
column chromatography using Sephadex G-75. Three peaks of radioactivity 
were eluted, the first represented the damaged hormone aggregates, the 
second represented the labelled hormone and third was of free iodine. The 
specific activit)' of purified labelled hormone was calculated. 
Before the binding assay of prolactin binding sites, desaturation of 
occupied receptors from endogenous prolactin was done since prolactin does 
not appear to dissociate from its receptors during membrane preparation. 
For this, membranes were treated with high concentrations of MgCl2 prior to 
binding assays. 
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For the binding assay, membrane preparations were incubated with 
radio active hormone (PRL) overnight in the absence and presence of an 
excess of cold hormone. Specific binding was calculated as the difference 
between the radio activity bound in the absence (total binding) and in the 
presence of an excess cold prolactin (non-specified binding). These data were 
expressed as the percentage of the total radioactivity added. 
Pure plasma membrane preparation of malignant tissue that were 
checked by electron microscope and by the presence of positive - marker 
enzyme showed two bands by immunobloting. These bands may be con-
sidered to be of prolactin (25 K Dal) and its variant (29 K Dal). Binding study 
for prolactin had shown low amount of prolactin receptor in crude malignant 
breast tissue. However the purified plasma membrane of these did not show 
any binding for prolactin. 
From the present study it could be concluded that there are specific 
binding sites for peptide hormones in human pathological breast tissue. These 
could be located immunocytochemically in the formalin fixed paraffin em-
bedded breast tissue slides as well as in fine needle aspirates of the breast 
lumps. The staining was heterogenously distributed. Breast carcinoma 
showed more consistent staining as compared to benign breast disease. Also 
prolactin receptors could be located biochemically in the malignant breast 
tissue membranes preparafions. Prolactin binding sites were present in 
receptor concentration in post menopausal patients were consistent with the 
results of the study that the prolactin plasma levels are elevated in post 
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menopausal patients. Post menopausal patients were also reported to have 
more estrogen receptors. Estrogens are reported to stimulate prolactin secre-
tion andincrease prolactin receptors in breast. Presence of prolactin binding 
sites in metastasing tumours may also indicate that aggressive breast cancer 
were associated with the secretion of an unknown factor acting at the 
hypothalamic pituitary level to enhanced prolactin secretion which in turn 
increases tissue prolactin binding sites, or perhaps that the tumour itself 
secretes prolactin. 
The presence of prolactin binding sites in malignant tumours of breast 
would thus indicate that prolactin might be significant in the support of breast 
cancer growth in vivo. 
Presence of prolactin binding sites in benign breast disease is of great 
importance. The apocrine change that is associated with high breast cancer 
risk had specific prolactin binding sites. This finding may also suggest a role 
of prolactin in the etiology of breast cancer through the indication of apocrine 
change. 
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